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2. ABBREVIATIONS 
 
AEC aminoethylcarbazole 
AIF apoptosis inducing factor 
Apaf 1 apoptotic protease activating factor 1 
APC antigen presenting cell 
AsPC-1 human pancreatic cell line 
ATP adenosine triphosphate 
Bag3 Bcl-2-associated athanogene 3 
Bak Bcl-2 homologous antagonist/killer 
Bax Bcl-2 associated X protein 
Bcl-2 B-cell lymphoma 2 
BID BH3 interacting-domain death agonist 
BSA bovine serum albumin 
CD cluster of differentiation  
CHPP continous hyperthermic peritoneal perfusion 
CRT calreticulin 
DC dendritic cell 
DAB 3,3’ diaminobenzidine 
DAMP damage associated molecular pattern 
DAPI 4’,6 diamidino-2-phenylindole 
dATP deoxyadenosine triphosphate 
DMEM Dulbecco’s modified Eagle’s minimal essential medium 
DNA deoxyribonucleic acid 
DNAJB DnaJ (Heat shock protein 40) homolog, subfamily B 
DIABLO direct IAP-binding protein with low pI 
dUTP 2'-deoxyuridine 5'-triphosphate 
ECL electrochemiluminescence 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
FADD Fas-associated protein with death domain 
FASL Fas ligand 
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FCS fetal calf serum 
FFPE formalin-fixed paraffin-embedded 
FOV field of views 
HIPEC hyperthermic intraperitoneal chemotherapy 
HMGB1 high mobility group box 1 
HRP horseradish peroxidase 
HSF heat shock factor 
Hsp70 heat shock protein 70 
Hsp90 heat shock protein 90 
HSPA heat shock protein 70 A 
HT29 human colorectal adenocarcinoma cell line 
HTRA2 high temperature requirement protein A2 
H&E hematoxylin and eosin 
IAP inhibitor of apoptosis 
ICD immunogenic cell death 
Ig immunogloubulin  
log2FC binary logarithm of fold change 
mEHT modulated electrohyperthermia 
MHC major histocompatibility complex 
MIAME Minimum information about a microarray experiment 
MIAPaCa-2 human pancreatic cell line 
min/h minute per hour 
MLS mitochondrial localization signal 
MMP mitochondrial membrane permebilization 
MPO myeloperoxidase 
mRNA messenger ribonucleic acid 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NK natural killer 
PS phosphatidilserin 
PVDF polyvinylidene difluoride 
RAGE receptor advanced glycation endproducts 
RIN RNA integrity number 
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RIP1 receptor-interacting serine/threonine-protein kinase 1 
RIP3 receptor-interacting serine/threonine-protein kinase 3 
rMA relative mask area 
RNA ribonucleic acid 
ROS reactive oxygen species 
SAM significance analysis of microarrays 
SAR specific absorption rate 
SAS human tongue squamous cell carcinoma cell line 
SDS-PAGE sodium dodecylsulfate polyacrylamide gel 
tBID truncate BH3 interacting-domain death agonist 
TBS Tris-buffered saline 
TDE tumor destruction efficiency 
TDR tumor destruction ratio 
TdT terminal deoxynucleotidyl transferase 
TER thermal enhancement ratio 
TIM3 T-cell immunoglobulin domain and mucin domain 3 
TLR2/4 Toll like receptor 2/4 
TMA tissue microarray 
TNFα tumor necrosis factor α 
TNFα-R1 tumor necrosis factor α receptor 1 
TRAIL TNF-related apoptosis-inducing ligand 
TRAIL-R1 TNF-related apoptosis-inducing ligand receptor 1 
TRAIL-R2 TNF-related apoptosis-inducing ligand receptor 2 
TUNEL terminal deoxynucleotidyl transferase dUTP nick end labeling 
WBH whole body hyperthermia 
WGA wheat germ agglutinin 
εk complex permittivity 
σk complex conductivity 
T temperature difference 
t time difference 
Eloc average local electric field 
ρ density of a material 
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3. INTRODUCTION 
 
3.1. Characteristics of hyperthermia in oncology 
The term hyperthermia in oncology refers to techniques of heat application administered to 
tissues as an adjunct to conventional strategies of cancer treatment such as chemo- or 
radiotherapy. (Hildebrandt et al. 2002). The aim of hyperthermia treatment is, like any 
oncological therapies, to completely and selectively destroy the malignant tissue (Szasz et 
al. 2010). Hyperthermia is mostly identified with a range of temperature of the target 
between 40-48°C maintained at a treated site for a period of one hour or more each time 
(Chicheł et al. 2007). From this loose definition it becomes clear that this is a rather 
heterogeneous group of treatments with diverse efficiency and outcome depending on the 
source of heat generation and the histogenesis, differentiation, site/microenvironment and 
the defective regulatory pathways of the treated tumors. 
 
3.1.1. Forms of hyperthermia 
The main forms of hyperthermia include whole body hyperthermia, hyperthermic perfusion 
techniques and local/regional hyperthermia (Hildebrandt et al. 2002). 
Whole body hyperthermia (WBH) is used for patients with metastatic disease usually in 
combination with chemotherapy. It can be performed by thermal chambers, hot water 
blankets or infrared radiators. In extreme WBH the patient core temperature is heated up to 
42°C for 60 minutes under general anesthesia or deep sedation, while in moderate WBH the 
patient core temperature is heated up between 39.5-41°C for 3-4 hours (Chicheł et al. 
2007). A few phase II studies were carried out using WBH in combination with 
chemotherapy. WBH was applied with oxaliplatin, leucovorin and 5-fluorouracil treating 
patients with metastatic rectal tumors with a 20% response rate (Hegewisch-Becker et al. 
2002). Recurrent ovarian cancer and recurrent and metastatic ovarian cancer patients were 
treated with WBH in combination with carboplatin with a response rate of 45% (Atmaca et 
al. 2009) and 33% (Richel et al. 2004) respectively. The phase II study of metastatic soft 
tissue sarcoma patients treated with WBH in combination with fosfamide, carboplatin and 
etoposide revealed a 28.4% response rate (Westermann et al. 2003). 
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Hyperthermic perfusion techniques include hyperthermic isolated limb perfusion and 
hyperthermic intraperitoneal perfusion with or without administering a chemotherapy agent 
(hyperthermic intraperitoneal chemotherapy- HIPEC, continuous hyperthermic peritoneal 
perfusion- CHPP) (Wust et al. 2002; Chicheł et al. 2007). HIPEC proved to be beneficial 
for patients with peritoneal cacinomatosis from appendicial cancer, colorectal cancer, 
ovarium cancer and peritoneal mesothelioma (Chua et al. 2009). The median survival was 
found to be between 26 to 56 months in ovarian cancer with peritoneal carcinomatosis 
when cytoreductive surgery was used with HIPEC (Chua et al. 2009). In colorectal cancer 
with peritoneal carcinomatosis the median disease specific survival was found to be 
22.2 months when cytoreductive surgery was applied with HIPEC while it was 12.6 months 
in the control arm (Aoyagi et al. 2014). Hyperthermic isolated limb perfusion is a technique 
bypassing a large supplying artery and a vein of a limb to deliver heat to drained blood in 
an extra corporal way (Chicheł et al. 2007). This method has fewer side effects than WBH, 
mostly administered in combination of chemotherapy in melanomas or soft tissue sarcomas 
(Chicheł et al. 2007). Hyperthermic isolated limb perfusion may be used to treat malignant 
melanomas with an overall median response rate of 90% (Moreno-Ramirez et al. 2010) or 
soft tissue sarcomas with an overall response rate of 81.5% (Trabulsi et al. 2012).  
Local hyperthermia is applied to tumors of relatively small size, while regional 
hyperthermia is used to heat up a body region involving the tumor. For such heating 
infrared radiation, microwaves, radio waves and ultrasound can be used (Szasz et al. 2002; 
Chicheł et al. 2007). The following sections will briefly summarize what is known about 
the biophysical background, major characteristics and utilization for cancer treatment of 
local hyperthermia. 
 
3.1.2. Theoretical background of local hyperthermia  
Oncological hyperthermia uses heat energy to destroy the malignant cells. The absorbed 
energy is converted to heat, which further leads to increment on temperature. Therefore, 
one has to distinguish heat (as the absorbed energy) and the resulted elevation of 
temperature as a consequence of energy absorption. Local/regional hyperthermia works by 
energy/heat absorption in the targeted tissue volume. Although, blood flow can reduce the 
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efficiency of energy absorption by cooling the heated volume incorporating the tumor 
tissue (Szasz et al. 2010). 
 
3.1.3. Pre-clinical observations and results 
To provoke the cytotoxic effect of hyperthermia either in vitro or in vivo, usually a water 
bath is applied for generating heat within a therapeutic range of temperature and duration. 
For example human head and neck squamous cell carcinoma cell line xenografted to the 
hind leg of BALB/cA Jcl-nu mice, (Tamamoto et al. 2003) or HT29 human colorectal 
carcinoma cell line xenografted to NCI Nu/nu mice (Sun et al. 2008) or HT29 xenografted 
to BALB/C nu/nu mice were tested in this way (Liang et al. 2007). 
Hyperthermia can inhibit DNA, RNA and protein synthesis during the treatment, but RNA 
and protein synthesis rapidly recover after the treatment (Hildebrandt et al. 2002). The 
DNA synthesis is inhibited due to denaturation of proteins involved in DNA repair such as 
DNA-polymerase α and β and Rad51 (Hildebrandt et al. 2002; Genet et al. 2013). Heat can 
change the fluidity of the cell membrane resulting in the softening or melting of the lipid 
bilayer. This leads to the accumulation of cholesterol and ceramide in the lipid layer 
resulting in the rearrangement of the lipid rafts with concomitant changes in the protein 
content such as phospholipase A2 and phospholipase C causing either calcium release from 
the ER or the transcriptional activation of heat shock proteins (Hsp) (Csoboz et al. 2013). 
The heat stress related to hyperthermia on the other hand may induce heat shock protein 
(Hsp) synthesis through protein aggregation and denaturation followed by heat shock factor 
(HSF) binding to the promoter regions of different Hsp’s (Hildebrandt et al. 2002). The 
elevated intracellular Hsp concentration can be cytoprotective (Horvath et al. 2010), may 
translocate to the cytoplasm membrane, where it either protects the cell (Horvath et al. 
2010) or act as an immunostimulant (Nishida et al. 1997; Hildebrandt et al. 2002). 
Hyperthermia can lead to necrosis and programmed cell death in a tremperature dependent 
manner in a murine mastocytoma cell line (Harmon et al. 1990) and in several 
hematological tumor cell lines (Harmon et al. 1990; Baxter et al. 1992; Gabai et al. 1995; 
Yonezawa et al. 1996). However, hyperthermia in vivo is usually used for targeting solid 
tumors. Unfortunately the anti-tumor efficiency of hyperthermia can vary depending on the 
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models used. Hyperthermia for 1h at 43.5°C induced DNA fragmentation 6h post-treatment 
in Dunn osteosarcoma cell line (Rong et al. 2000) and for 44 min on 44°C in human tongue 
squamous cell carcinoma cell line (SAS) (Kajihara et al. 2008). On the other hand 
hyperthermia was not found to be effective either at 42°C in colorectal cancer cell line 
(HT29) (Shchepotin et al. 1997), or at 43°C when used for 1h in pancreatic cancer cell lines 
(AsPC-1, MIAPaCa-2) (Adachi et al. 2009). In vivo however, instead of water bath infrared 
radiation, microwave or radiofrequency is applied for generating heat. 
Beside the cellular and cytotoxic effects, hyperthermia can regulate blood flow by elevating 
blood flow/perfusion up to ~42
oC and reducing it above 42°C. This can be exploited in 
combination with chemotherapy for elevating the local concentration of chemotherapeutic 
agents by moderate hyperthermia (Hildebrandt et al. 2002). 
 
3.1.4. Clinical observations 
Hyperthermia is usually applied in combination with radiotherapy, chemotherapy or both. 
As mentioned above hyperthermia below 42°C can increase the blood flow, which is 
reduced above this temperature. In clinical conditions local/regional hyperthermia in most 
of the cases does not exceed 42°C, therefore, this is the basis of combinational therapy 
(Hildebrandt et al. 2002). When hyperthermia and radiation therapy act synergistically the 
term “thermal radiosenzitization” is used, which is most prominent in S-phase proliferating 
cell fractions that are usually resistant to radiotherapy (Hildebrandt et al. 2002). To define 
the benefit of the combinational therapy thermal enhancement ratio (TER, the quotient of 
survival fraction of cells treated with radiation alone or with radiation and hyperthermia in 
combination) is used (Overgaard 1984; Hildebrandt et al. 2002). Hypoxic cells, cells with 
impaired nutrient supply and/or acidic pH, react sensitively to combined therapy of heat 
and radiation (Dewey et al. 1977; Dewey 1994). Synchronous application of the combined 
therapy would be the best routine; however, technical difficulties still need to be overcome 
for this to be carried out. Therefore, in clinical practice heat and radiation are applied after 
one and other within a short period of time. Some prefer applying radiation first followed 
by heat within 2-4 hours, while others apply heat prior to irradiation. So far, neither of these 
strategies has been tested by randomized clinical studies (Hildebrandt et al. 2002). 
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The term “thermal chemosenzitization” is used in analogy with thermal radiosensitization, 
for indicating synergy between hyperthermia and chemo- or radiotherapy. The applicability 
of chemotherapeutic agents in combination with hyperthermia depends on pharmacokinetic 
properties of the drug. For example drugs which are metabolized in the liver should be 
applied a few hours before hyperthermia (e.g.: cyclophosphamide, ifosfamide). One would 
expect that changes in tumor blood supply will affect the distribution of the drug in the 
malignant tissue. In reality, this interaction is highly complex and depends much more on 
environmental factors such as fluid balance and pH in addition to blood supply, than 
radiation and heat (Hildebrandt et al. 2002).  
So far a few randomized trials have been carried out i.e. where hyperthermia was combined 
with radiotherapy of head and neck tumors and breast cancers with a complete response 
rate of 32% with hyperthermia and 30% without hyperthermia, (Perez et al. 1991; 
Hildebrandt et al. 2002). Hyperthermia was used together with chemotherapy of soft tissue 
sarcomas with a response rate of 28.8% in the combination group and 12.7% in the 
chemotherapy group (Issels et al. 2010). A phase II study was performed on locally 
advanced rectal tumors (T4) with an 83% disease free survival in the 24.9 months median 
follow up time. (Barsukov et al. 2013). 
 
3.2. Principles of modulated electrohyperthermia  
Modulated electrohyperthermia (mEHT), a subtype of local/regional hyperthermia, is a 
non-invasive technique for targeted tumor treatment using 13.56 MHz radiofrequency with 
1/f amplitude modulation. Besides the thermal effect of the electric field generated by 
mEHT, the electric field itself also has a tumor destructing effect (Andocs et al. 2009), 
however its mechanism of action has not been described yet. 
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3.2.1. Bioelectrodynamic description of tissues 
3.2.1.1. Conditions and variables 
Biological materials can be described by complex permittivity and complex conductivity 
(Mátay et al. 2000).  
Complex permittivity (εk) is related to the dipole content of the biological material, due to 
the cytoplasmic and extracellular macromolecules and the membrane bound 
macromolecules. Tissue molecules as dipoles will rotate upon the influence of an exciting 
electric field. This rotation will be asynchronous with the electric field due to the inertia 
and the internal friction of the dipoles, this is called dielectric relaxation, which is time 
dependent. This relaxation results in dispersion which is highly frequency dependent 
(Mátay et al. 2000). The relaxation can be described by more than one relaxation constants 
α, β, γ and δ (Figure 1). Each domain is determined by relaxation frequencies. α dispersion 
( < 1 kHz) can be explained by the cell membrane capacitance. The capacitance decreases 
from 20 µF/cm2 to 1 µF/cm2 with the elevation of the frequency (1 Hz - 1 kHz.) This 
decrement is caused by the elevated ion current through the plasma membrane. β dispersion 
(1 kHz-10 MHz) is related to the accumulation of the dielectric material on the cell 
membrane surface. γ dispersion (in the GHz range) is linked with the relaxation of the 
bound water (Blad et al. 1996; Mátay et al. 2000; Zou et al. 2003). A small δ dispersion 
exists between β and γ dispersion frequencies (not visible in Figure 1), related to bound 
water on the macromolecules and the charged proteins (Schwan 1957; Mátay et al. 2000). 
Besides dipoles, biological materials also contain free charges which can drift upon 
influence by the electric field. To describe this drifting we use the term complex 
conductivity (σk), which is also frequency dependent (Figure 1) (Mátay et al. 2000).  
The interference between radiofrequency field and the biological material can result in 
thermal and non-thermal effects. The thermal effect is related to the rotation of dipoles and 
the concomitant friction, resulted in electric displacement of the electric field (Mátay et al. 
2000). 
The permittivity and the conductivity are characteristic to the biological material itself and 
not the electric circuit (Mátay et al. 2000). 
DOI:10.14753/SE.2015.1802
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Figure 1. The frequency dependent relaxation of real part of permittivity and the 
frequency dependency of the real part of conductivity. The graph is showing the real 
part of complex permittivity relaxation, pointing out α, β and γ dispersion and real part of 
complex conductivity. ε’ is the real part of complex permittivity, σ’ is the real part of 
complex conductivity [S/m], while the ‘x’ axis is the frequency of the applied field. 
(Scholoz et al. 2000)  
 
As a summary in all biological materials bioelectrodynamic properties can be simplified to 
the description of complex permittivity (εk) (resulted from the dipole content), complex 
conductivity (σk) (resulted from the free charges) and to the dispersion properties (resulted 
from the distinct relaxation at different frequencies) (Mátay et al. 2000; Szasz et al. 2010). 
 
3.2.1.2. Bioelectrodynamic characteristics of malignancies 
As it was mentioned above the dielectric permittivity and the complex conductivity of 
tissues are highly frequency dependent. As it is characteristic to the material itself, different 
biological materials (tissues) have clearly different bioelectric properties (σ and ε). In the 
liver conductivity is 0.15 S/m at 10kHz, 0.16 S/m at 100kHz, 0.47 S/m at 10MHz and 
0.9 S/m at 100MHz. In the lung it is 0.11 S/m at 10kHz, and 0.8 S/m at 100MHz. In the 
spleen it is 0.62 S/m at 100kHz, 0.84 S/m at 10MH and 1.05 S/m at 100MHz. In the kidney 
it is 0.24 S/m at 100kHz, 0.64 S/m at 10MHz and 0.94 S/m at 100MHz. It is obvious for 
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example that the conductivity of the spleen is higher than that of the liver or the lung. The 
difference of σ or ε between the different tissues on diverse frequencies is not linear. 
(Foster 2000; Raoof et al. 2013)  
If we compare the bioelectric properties of malignant and non-malignant tissues at the same 
frequency, malignant tumors show higher permittivity (ε) and conductivity (σ) than normal 
tissues (Pethig et al. 1984; Blad et al. 1996; Zou et al. 2003; O'Rourke et al. 2007). For 
example, in breast tissue in the range of 3MHz-3GHz, σ of the normal tissue increases from 
1.5 to 3 mS/cm, while σ of malignant breast tumors increases from 7.5-12 mS/cm, while ε 
of the normal tissue remains 10 and of the malignant it increases from 50 to 400. There is a 
4-fold increase in conductivity and 5 to 40 fold increase in permittivity for the benefit of 
tumors compared to normal tissues (Zou et al. 2003). 
The elevated conductivity can be explained by the altered metabolism of the tumor cells. 
This is called aerobic glucolysis or the Warburg effect. The high rate of glucose uptake and 
lactate production results in an increased ion concentration and concomitant increased 
conductivity (Szasz et al. 2010). On the other hand the altered electrical properties of 
malignant tissue are attributed to increased cellular water and salt content, as well as altered 
membrane permeability of the tumor cells (Pethig et al. 1984; Blad et al. 1996; Scholoz et 
al. 2000; Zou et al. 2003; O'Rourke et al. 2007). 
 
3.2.2. Biophysical background of modulated electrohyperthermia 
Modulated electrohyperthermia is a non-invasive technique using capacitive coupled (the 
targeted tissue is put between the condenser electrodes) 13.56 MHz radiofrequency with 1/f 
amplitude modulation to target tumor tissue. 
This specific frequency is used because of the following reasons. The applied 
radiofrequency has to penetrate deeply into and across the body. The penetration depth 
depends on the frequency used, as well as permittivity and conductivity of the targeted 
tissue. Therefore, at a fixed frequency the penetration depth is higher e.g. through the same 
thickness of homogenous fat than of homogenous muscle (Cheung 1982). In order to 
ensure that capacitive coupled radiofrequency penetrates into and across the average human 
body thickness the frequency has to be below 25 MHz (Szasz et al. 2010). The applied 
DOI:10.14753/SE.2015.1802
15 
 
frequency has to be safe, not to trigger nerve excitation, preferable to be between 10 kHz 
and 1 GHz (Szasz et al. 2010) and has to be in the range of β dispersion (around 10 MHz) 
to influence cell membranes including their embedded receptors (Szasz et al. 2010). It is 
also practical to be in a free frequency range, which does not need shielding for avoiding 
interference with other electronic devices. All these criteria meet at 13.56 MHz (Szasz et al. 
2010). 
The selectivity of mEHT is based on the difference in σ and ε values between malignant 
and non-malignant tissue on 13.56 MHz. Significant difference in these values was found 
among breast cancer, pancreatic carcinoma, and hepatocellular carcinoma cell lines but in 
all cases both the permittivity and conductivity significantly exceeded of those found in the 
related normal cells (Zou et al. 2003; Raoof et al. 2013).  
The thermal effect of the electromagnetic field is associated with the absorbed energy by 
the tissue; it is described by the specific absorption rate (SAR) (Mátay et al. 2000).  
 
    
 
 
    
   (1) 
 
where σ is the conductivity, ρ the density of the material, while Eloc is the average local 
electric field.  
Changes in the temperature, as a thermal effect, can be described by the following: 
 
   
 
 
      (2) 
 
where ΔT is the temperature difference in Δt time difference and C is the specific heat of 
the biological material. 
Therefore SAR can be used as the dose of the thermal effect of electromagnetic field. 
On the other hand, in the interaction between the electric field and the biological material a 
non-thermal (or non temperature dependent) effect can also be described related to the non 
thermal equilibrium (Mátay et al. 2000). It was shown that mEHT has such effect on HT29 
(human colorectal adenocarcinoma cell line) cancer xenograft model, where the thermal 
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and non-thermal effects act in synergy for tumor destruction, but the molecular mechanism 
of these effects were not explained (Andocs et al. 2009). 
 
3.2.3. Clinical observations using modulated electrohyperthermia 
So far, mainly the thermal effect is taken into consideration when mEHT is used in clinical 
practice. Therefore, mEHT represents a heating method in hyperthermic oncology. 
There have been several case reports and retrospective studies published on the benefits of 
using hyperthermia for anti-tumor therapy (Szasz et al. 2010). Though mEHT treatment can 
interfere with tumor tissue in monotherapy it has been used for hyperthermic oncology in 
phase I and phase II clinical studies in combination with chemo- and/or radiotherapy of 
brain, liver, breast and gastrointestinal malignancies (Brazma et al. 2001; Fiorentini et al. 
2006; Fiorentini et al. 2006; Wismeth et al. 2010). For instance, compared to the published 
30-33 weeks median overall survival, temozolomide-based chemotherapy and radiotherapy 
supported with mEHT resulted in 36 weeks median overall survival (n = 12) with one 
complete and two partial remissions (response rate 25%) in recurrent malignant gliomas 
(Fiorentini et al. 2006). Also, fluorouracil based chemotherapy combined with mEHT 
resulted in 24.1 months median overall survival in liver metastatic primary colorectal 
cancers (n = 90) compared to the 12 month median survival reported when fluorouracil 
chemotherapy was used alone (Hager et al. 1999). Also, it has already been used in 
combination with chemo– and radiotherapy with benefit for treating recurrent breast cancer 
(Feyerabend et al. 2001). 
 
3.3. Theoretical background of the observed biological impact of hyperthermia 
Several studies have proven that hyperthermia can cause different cell death forms under 
various programmed cell death subroutines (e.g. caspase dependent apoptosis or autophagic 
cell death) and accidental necrosis at a heat absorption dependent manner (Hildebrandt et 
al. 2002). In vitro circumstances caspase dependent programmed cell death was proven in 
cervical cancer cell line and in osteosarcoma cell line (Zhou et al. 2011; Hou et al. 2014). 
Hyperthermia induced DNA fragmentation was found in human head and neck squamous 
cell carcinoma cell line and in murine fibrosarcoma cell line in vitro without further 
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specifying the exact programmed cell death subroutine (Tamamoto et al. 2003; Lui et al. 
2010). In HT29 cell line in vitro cell death subroutines were contradictory (Chen et al. 
2008; Makizumi et al. 2008) though in vivo the upregulation of Bax protein was found 
without further clarifying the cell death mechanism (Liang et al. 2007). Accordingly, 
hyperthermia related cell death mechanism needs to be specified  in vivo in different tumor 
types. 
 
3.3.1. Characteristics of cell death forms 
For the definition of different type of cell death forms we first have to define the first 
irreversible phase within cell damage, the so called “point of no return” and then the 
characteristics of a dead cell.  
The “point of no return” in a cell’s fate can usually be characterized by (1) a massive 
caspase activation, which is part of the classic apoptotic program. However, caspase 
independent death may also occur, moreover, caspases might also be involved in non-lethal 
pathways such as cell differentiation and activation. Further feature is the loss of 
mitochondrial transmembrane potential (2), which is usually preceded by mitochondrial 
membrane permeabilisation (MMP). The complete MMP (3) results in the liberation of 
lethal catabolic enzymes or activators. Finally, the phosphatidilserin (PS) exposure (4) from 
the inner to the outer leaflet of the plasma membrane can also be a sign of irreversible cell 
damage (Kroemer et al. 2005; Kroemer et al. 2009). 
The main characteristics of cell death are: loss of plasma membrane integrity (1); blebbing 
of the cytoplasmic membranes and shrinkage of nuclear chromatin followed by the 
complete fragmentation of the cell including the nucleus (2); the occurrence of discrete 
nuclear bodies (referred to as “apoptotic bodies”) (3) and finally, the engulfment of cells’ 
corps by adjacent cells or phagocytes (4) in vivo (Kroemer et al. 2005; Kroemer et al. 
2009). 
Several subroutines of programmed cell death forms exist including apoptosis, 
necroptosis/regulated necrosis, autophagic cell death, mitotic catastrophe, netosis, 
parthantos, pyroptosis, anoikis, entosis and cornification (Galluzzi et al. 2012).  
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Apoptosis was first described as a specific morphological aspect of cell death by Kerr in 
1972 (Kerr et al. 1972; Elmore 2007). It was first investigated occurring during the 
development of Caenorhabiditis elegans, which is made up of 1090 somatic cells in an 
adult worm of which 131 undergoes the apoptotic process during development (Elmore 
2007). The morphological signs of apoptosis are reduction of cellular volume (pycnosis), 
chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing 
(Elmore 2007; Kroemer et al. 2009; Galluzzi et al. 2012). For the molecular 
characterization we have to differentiate extrinsic and intrinsic apoptosis, which can be 
caspase dependent and independent (Galluzzi et al. 2012). Extrinsic apoptosis can be 
initiated by a death ligand (e.g. FASL, TNFα and TRAIL) through death receptors (e.g. 
FAS, TNFα-R1, TRAIL-R1 and TRAIL-R2). Alternatively, extrinsic apoptosis can also be 
initiated by dependence receptors (netrin receptors) which exert lethal functions when the 
concentration of their specific ligand falls below a critical threshold (Galluzzi et al. 2012).  
Extrinsic apoptosis would undergo one of the three major signaling cascades: (1) death 
receptor signaling, activation of caspase-8 followed by the activation of the effector 
caspase-3 or (2) death receptor signaling activation of caspase-8 cleavage of BID (tBID) 
resulting in MMP followed by caspase-9 and caspase-3 activation. Ligand deprivation-
induced dependence receptor signaling (3) followed by caspase-9 and caspase-3 cascade 
activation (Galluzzi et al. 2012). 
Intrinsic apoptosis can be triggered by intracellular stress such as DNA damage, oxidative 
stress, cytosolic Calcium overload, accumulation of unfolded proteins in the endoplasmic 
reticulum (ER), radiation, hypoxia, hyperthermia, viral infection or free radicals (Elmore 
2007; Galluzzi et al. 2012). As a result of intracellular stress pores are formed in the 
mitochondria membrane leading to release of intermembrane space proteins to the 
cytoplasm (Elmore 2007; Galluzzi et al. 2012). The mechanism of pore formation can be 
achieved by induction of mitochondrial permeability transition, in which non-specific pores 
are opened in the outer and the inner membranes of the mitochondria. This can occur in 
both programmed cell death and accidental necrosis (Gogvadze et al. 2006). The second 
option for pore formation is the outer membrane permeabilisation by Bcl2 (B-cell 
lymphoma 2) family pro-apoptotic proteins, such as Bax (Bcl-2 associated X protein) and 
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Bak (Bcl-2 homologous antagonist/killer) occurring in the apoptotic cascades (Gogvadze et 
al. 2006; Galluzzi et al. 2012). Also, hypotonicity and the modulation of ionic fluxes can 
lead to mitochondrial membrane permeabilisation (Gogvadze et al. 2006). Once the pores 
are formed, the mitochondrial transmembrane potential decreases and the intermembrane 
space proteins are released to the cytosol, such as cytochrome c, apoptosis inducing factor 
(AIF), endonuclease G, direct IAP-binding protein with low pI (DIABLO) and high 
temperature requirement protein A2 (HTRA2) (Galluzzi et al. 2012). 
If the intermembrane space protein release is followed by a caspase dependent subroutine, 
then the cytochrome c and Apaf1 (Apoptotic protease activating factor 1) (with d9ATP) 
will form the apoptosome, which will further trigger the activation of pro-caspase-9 and the 
effector cascase-3.  
On the other hand mitochondrial AIF and endonuclease G can also tranaslocate to the cell 
nucleus, where they can mediate large scale DNA fragmentation on a caspase independent 
manner. AIF is synthesized in the cytoplasm as a 67 kDa protein with a mitochondrial 
localization signal (MLS) in the N terminus. Once it is imported to the mitochondria MLS 
is removed resulting in a 62 kDa mature protein. During the mitochondrial pore formation a 
soluble 57 kDa fragment is cleaved form AIF, released from the intermembrane space and 
transferred to the nucleus (Norberg et al. 2010). Although AIF does not have a canonical 
DNA binding domain but has a positive charged surface which can bind to the negative 
charged phosphate backbone of the DNA (Natarajan et al. 2012). 
For a long time, necrosis was only considered as an accidental cell death mechanism, 
however, it can occur also in a regulated manner referred to as programmed necrosis 
(Galluzzi et al. 2012). It can be triggered by the same ligands and receptors as extrinsic 
apoptosis (Denecker et al. 2001; Nicotera 2002; Christofferson et al. 2010; Vandenabeele et 
al. 2010; Han et al. 2011), but caspases are inhibited, therefore RIP1 (receptor interacting 
serin/threonin-protein kinase 1) and RIP3 (receptor interacting serin/threonin-protein kinase 
1) are not degraded and activate the execution of regulated necrosis (Galluzzi et al. 2012). 
RIP1 can be activated by autophosphorilation on Ser161 and dimerization. RIP3 can be 
phosphorilated on Ser199 leading to its activation (Christofferson et al. 2010). Regulated 
necrosis can occur on RIP1 dependent manner or RIP3 dependent but RIP1 independent 
DOI:10.14753/SE.2015.1802
20 
 
manner (Galluzzi et al. 2012). Although the initiation of necroptosis is known the 
downstream execution mechanism is still unclear (Christofferson et al. 2010; 
Vanlangenakker et al. 2012). 
Autophagic cell death is characterized by a massive cytoplasmic vacuolization. This kind of 
cell death can be related to some types of cancers which lack modulators like Bax, Bak or 
caspases. In most cases autophagy acts as a cytoprotective response, only when it fails to 
protect the cell it turns into a cell death mechanism (Galluzzi et al. 2012).  
 
3.3.2. Characteristics of immunogenic cell death forms 
Apoptosis was considered as an immunologically silent form of cell death, however, 
recently it has been revealed that some lethal stimuli can lead to an immunogenic way of 
cell death (Kroemer et al. 2009; Krysko et al. 2012). Immunogenic cell death (ICD) is a 
form of programmed tumor cell death. In overlap with the molecular signs of programmed 
cell death the spatiotemporal occurrence of the damage associated molecular pattern 
(DMAP) is required for professional antigen presenting cells to trigger an antitumor 
immune response. (Scheffer et al. 2003; Ullrich et al. 2008; Kepp et al. 2011; Garg et al. 
2012; D'Eliseo et al. 2013; Ladoire et al. 2013). ICD is known to be provoked by massive 
cell stress in synergy with programmed cell death (Kepp et al. 2009; D'Eliseo et al. 2013; 
Krysko et al. 2013; Ladoire et al. 2013) triggered by chemotherapeutic agents (doxorubicin, 
oxaliplatin etc.) (Tesniere et al. 2010; Ladoire et al. 2013), cardiac glycosides (Menger et 
al. 2012), hypericin based photodynamic therapy (Castano et al. 2006; Mroz et al. 2011; 
Garg et al. 2012) or capsaicin (D'Eliseo et al. 2013). It is of note, however, that these 
interventions can generate slightly different DAMP patterns (Garg et al. 2013; Kroemer et 
al. 2013). 
The DAMP sequence, relevant to induce ICD in tumor cells include the pre-apoptotic 
surface exposure of calreticulin (CRT), the surface appearance of heat shock proteins 
(Hsp70 and Hsp90) and ATP release at early apoptotic stages, followed by passive release 
of high mobility group box 1 (HMGB1) as well as Hsp70 and Hsp90 at the late stages 
(Garg et al. 2010; Kepp et al. 2011; Garg et al. 2012; Martins et al. 2012; D'Eliseo et al. 
2013; Garg et al. 2013; Ladoire et al. 2013). 
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Calreticulin is mainly located in the endoplasmic reticulum, interacting with ERp57 and 
calnexin to maintain the proper protein folding. In the cytoplasm membrane ecto-
calreticulin, located in the lipid rafts, act as an ‘eat me‘ signal, where its life time is around 
12h. The calreticulin exposure occurs before any sign of an apoptotic event, however an 
apoptotic signal is required for this exposure. It is suggested that mitochondrial dysfunction 
and reactive oxygen species (ROS) production with secondary endoplasmic reticulum stress 
or local ROS generation at the endoplasmic reticulum or unfolded protein response 
pathway plays an important role in ecto-calreticulin translocation (Garg et al. 2010; Garg et 
al. 2013). Calreticulin translocation pathway is dependent on the inducer signal (Krysko et 
al. 2012). Ecto-calreticulin can be uptaken by phagocytes and professional antigen 
presenting cells (APC) through CD91 (Garg et al. 2010). Unfortunately, ecto-calreticulin 
driven tumor antigen uptake alone is not sufficient for antitumor immune response (Ladoire 
et al. 2013). 
Heat shock proteins are a family of conserved chaperones induced by cell stress including 
oxidative stress, irradiation, chemotherapeutic drugs, heat and electromagnetic field (Robert 
2003; Blank et al. 2009; Horvath et al. 2010). Tumors frequently show elevated Hsp70 
levels (Multhoff et al. 2011). In the cytoplasm, overexpressed Hsp70 can inhibit apoptosis 
and act as a cytoprotector (Horvath et al. 2010) maintaining protein homeostasis 
(Gehrmann et al. 2008). However, treatments using oxaliplatin, -radiation, anthracyclines, 
epidermal growth factor receptor specific antibody or hypericin based photodynamic 
therapy can trigger the cell membrane accumulation of heat shock proteins leading to ICD 
(Gehrmann et al. 2008; Garg et al. 2010; Krysko et al. 2012; Kroemer et al. 2013). On the 
other hand, cell membrane Hsp70 was also linked with the protection of membrane 
integrity under stress conditions (Horvath et al. 2010). Therefore, in tumor therapy, cell 
surface Hsp70 positivity has been associated both with negative prognosis, e.g. in lower 
rectal carcinomas and in squamous cell carcinoma of the lung (Pfister et al. 2007; 
Gehrmann et al. 2008) and also with improved outcome e.g. in gastric and colon 
carcinomas (Pfister et al. 2007). Unfortunately, it is not known how the membrane bound 
Heat shock proteins can translocate to the cell membrane from the cytoplasm (D'Eliseo et 
al. 2013) but it was suggested that membrane bound Hsp is associated with 
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phosphatidilserin in tumor cells and by a flip-flop mechanism, it can be exposed to the 
outer membrane leaflet into lipid rafts (Multhoff 2007). Heat shock proteins may have a 
crucial effect on initiating immune response on APCs and NK cells (Gehrmann et al. 2008; 
Garg et al. 2010). However, heat shock proteins alone on the cell surface are not enough for 
signaling immunostimulation, they have to form a complex in the cell membrane with a 
tumor peptide. This happens in paralel with the programmed cell death signaling 
(Gehrmann et al. 2008; Garg et al. 2010; Multhoff et al. 2011). Besides the immunogenicity 
of cell membrane Hsp70 (Gehrmann et al. 2008), extracellular heat shock proteins can 
directly boost the innate immune response (Multhoff et al. 2011). 
Both intracellular Hsp70 and Hsp90 assist in protein folding, by stabilizing proteins and 
preventing their degradation (Calderwood 2013). Membrane exposure of Hsp90 can be 
induced by bortezomib, anti-EGFR antibody (7A7) and hypericin-based photodynamic 
therapy (Garg et al. 2013). The surface exposure of Hsp90 may trigger DC activation signal 
required for cell-cell interaction between dying tumor cell and DC (Spisek et al. 2007), 
although the Hsp90 receptor on DC remains unknown (Garg et al. 2013). 
Release of HMGB1 represents a late signal of ICD with diverse roles. In the nucleus it acts 
as a non-histone chromatin binding protein interacting with the minor groove of DNA and 
regulatory molecules such as p53, NF-B and steroid hormone receptors (Kepp et al. 2011; 
Guo et al. 2013; Ladoire et al. 2013). Upon cell stress HMGB1 is released either from 
necrotic or apoptotic cells (D'Eliseo et al. 2013). Extracellular HMGB1 can be a cytokine-
like activator of macrophages, a chemotactant for neutrophils and a promoter of dendritic 
cell (DC) maturation (Guo et al. 2013). However, epigenetic and posttranslational 
modifications dictate HMGB1 further functions, its acethylation and phosphorilation on 
both nuclear localization signal leads to secretion to the cytpolasm. Hyperphosphorylation 
also relocates HMGB1 to the cytoplasm. HMGB1 may be oxidized in a caspase dependent 
manner or related to ROS production (Guo et al. 2013). The reduced HMGB1 usually binds 
to RAGE attenuating the pro-inflammatory activity but the oxidized protein binds to toll 
like receptor (TLR) 2/4 on the dendritic cells which may lead to tumor-specific immune 
response (Guo et al. 2013). However, if HMGB1 binds to TIM3 (T-cell immunoglobulin 
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domain and mucin domain 3) on tumor associated dendritic cells, it will inhibit anti-tumor 
activity (Guo et al. 2013). 
These DAMP signals combined with cancer antigens can stimulate the maturation of 
antigen presenting cells, which finally ‘cross-prime’ and activate anti-tumor T-cell 
immunity (Kepp et al. 2011; Sachamitr et al. 2012).  
 
As a summary, the altered bioelectrodynamic properties of cancer can result in the 
enrichment of electromagnetic field in the malignant compared to the normal tissues. Since 
mEHT, a form of hyperthermic therapy, uses electric field in the radiofrequency range 
(13.56 MHz) it can target the tumor tissue. The treatment related tumor cell death may 
occur in a programmed manner utilizing caspase dependent apoptosis, caspase independent 
apoptosis, programmed necrosis, autophagic cell death or accidental necrosis in the tumor 
tissue. Heat by itself can induce caspase dependent programmed cell death, autophagic cell 
death and accidental necrosis. In line with the treatment induced programmed cell death 
specific DAMP signals may appear on malignant cells which can potentially trigger 
specific anti-tumor immune response through DCs.  
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4. OBJECTIVES 
 
1. Determining tumor cell damage induced by a single shot of modulated 
electrohyperthermia (mEHT) treatment in an in vivo xenograft model set up using 
HT29, an aggressive colorectal cancer cell line, in Balb/c (nu/nu) 
immunocompromised mice. 
 
2. Investigating the molecular background of cell death induced by the mEHT 
treatment in the HT29 xenograft model. 
 
3. Characterizing additional, cell stress related molecular changes induced by mEHT 
in the HT29 xenograft model, which may promote antitumor immune response. 
Testing for damage associated molecular pattern (DAMP) sequence relevant to 
immunogenic cell death (ICD) response.  
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5. MATERIALS AND METHODS 
 
5.1.Tumor model  
HT29 colorectal adenocarcinoma cell line xenografted to Balb/c (nu/nu) mice were used to 
determine the molecular mechanism of cell damage induced by a single shot mEHT 
treatment. 
 
5.1.1. Cell line 
HT29 invasive colorectal adenocarcinoma cell line was propagated in Dulbecco’s modified 
Eagle’s minimal essential medium (DMEM)+ GlutaMax, high-glucose (4.5 g/l) medium 
including 10% heat inactivated fetal calf serum (FCS) and 1% streptomycin-penicillin 
(5000 units penicillin and 5 mg streptomycin/ml). Cells were released from a sub-confluent 
monolayer using 0.25% trypsin and 0.22 mg/ml ethylenediaminetetraacetic acid (EDTA) 
for 5 min and suspended in a serum free medium to reach the required 10
7
/ml cell 
concentration. All reagents were from GIBCO (Invitrogen, Carlsbad, USA). 
 
5.1.2. Animal model 
Female nude Balb/c (nu/nu) mice (provided by the Experimental Animal House of the 
National Research Institute for Radiobiology and Radiohygiene, Budapest, Hungary) 
maintained in sterile environment, kept on sterilized food and water ad libitum under 12 h 
dark/12 h light cycles. Both femoral regions of 6 to 8-week old mice were subcutaneously 
injected with 0.1 ml suspension of 10
7
/ml HT29 cells. The animals were treated using 
mEHT 18 days after HT29 cell injection, when the diameter of symmetrical tumor implants 
had reached ~1.5 cm. Laboratory animals were kept and treated in compliance with the 
Hungarian Laws No. XXVIII/1998 and LXVII/2002 on the protection and welfare of 
animals, and the animal welfare regulations of the European Union. The Governmental 
Ethical Committee approved the study under No. 22.1/609/001/2010. 
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5.2.Treatment conditions and sampling 
Tumor implants in the right legs of Balb/c (nu/nu) mice were placed into the plan-parallel 
electric condenser of the circuit. The circuit’s impedance was kept at a standard 50 Ohm 
and the electrode arrangement was asymmetrical. Animals were laid down on the 
rectangular grounded (lower) electrode made of polished aluminum of 72.0 cm
2
, which was 
kept at 37 °C during the treatment. A 2,5 cm2 round shaped electrode, made of flexible 
textile (copper-silver-tin coated woven fabric; Lorix Ltd. Bajna, Hungary), was overlaid on 
the tumor region for full skin contact and cooled from the outside using a wet pad 
(Figure 2). Electromagnetic field was generated at 13.56 MHz radiofrequency using 1/f 
amplitude modulation by a LabEHY instrument (both from Oncotherm Ltd, Paty, 
Hungary). 
Treatment groups involved 33 animals, which were delivered a single shot of mEHT for 
30 min at an average power of 4 W under 100 mg/kg Ketamine and 10 mg/kg Xylazine 
anesthesia. Parameters were adjusted to keep intratumoral temperature between 41-42 °C 
on the treated side (right leg), measured with optical sensors (Luxtron FOT Lab Kit, 
LumaSense Technologies, Inc. CA, USA). The subcutaneous temperature underneath the 
electrode was kept at ~40 °C and the rectal and the contralateral (untreated) tumor (left leg) 
core temperature was at ~37 °C. Sampling was made from both, treated (right leg) and 
untreated (left leg) sides 0, 1, 4, 8, 14, 24, 48, 72, 120, 168, and 216 h after treatment using 
3 mice in each group. Additional 5 sham treated control animals were sacrificed 3 at 24 h 
and 2 at 72 h post-treatment. All in all 38 mice were sacrificed resulting in 76 tumor 
samples. 
One half of the excised tumors was fixed in 10% formalin, dehydrated and embedded 
routinely into paraffin wax (FFPE). The other half was fresh-frozen in liquid nitrogen and 
kept at -80 °C in deep freezer until further testing.  
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Figure 2 Experimental setup of modulated electrohyperthermia (mEHT) treatment. 
A) Parameters of the electric field and tumor temperature between 41-42 
o
C during 
treatment are monitored. B) Thermal probes and electrode cooling of the treated right side. 
C-D) The electric field (red lines) is concentrated in the tumor implant (violet lump) 
between the condenser electrodes but cannot pass through cell membranes. 
 
5.3. Histomorphological analysis 
Whole cross sections from each (11) time point of all 76 (treated, untreated and sham 
treated control) tumor samples were stained for hematoxylin and eosin (H&E) for 
histomorphological analysis of signs of cell death. The stained slides were digitalized using 
Pannoramic Scan and analyzed with the HistoQuant module of Pannoramic Viewer 
software (all from 3DHISTECH, Budapest, Hungary) based on image color and intensity 
segmentation. The mEHT related tumor destruction ratio (TDR) was calculated by dividing 
DOI:10.14753/SE.2015.1802
28 
 
the area of destructed tumor tissue (D) by the whole tumor area (W) measured in whole 
cross sections. Treatment related tumor destruction efficiency (TDE) was assessed by 
dividing the TDR of the treated by the TDR of the untreated tumor of the same animal 
(Figure 3A). For statistical analysis the Kruskal-Wallis test of the SPSS Statistics v.20 
software (IBM Corp. New York, NY) was used. 
 
 
Figure 3 Histomorphological analysis and TMA core selection. A) The damaged tumor 
areas (circled in red) and the whole tumor areas (circled in blue) were delineated precisely 
in digital slides at high microscopic power (at x45 theoretical objective magnification) and 
measured with software. The tumor destruction ratio (TDR) value was calculated by 
dividing the area of destructed tumor tissue (D in red) by the whole tumor area (W in blue) 
measured in cross sections both of the treated (t) and untreated (u) tumors. The tumor 
destruction efficiency (TDE) of mEHT treatment was assessed by dividing the TDR of the 
treated tumor by the TDR of the untreated tumor of the same mouse. B) Standard regions of 
2 mm diameter from the damaged-intact tumor border (1 and 2) and from the damaged 
tumor center (3) were selected based on H&E stained slides. 
The number of apoptotic bodies was counted at x100 objective magnification in 10 
different microscopic fields of views (FOV) of 3 treated and 3 untreated samples at 48, 72 h 
post-treatment time points. Statistical analysis was carried out using SPSS Statistics v.20 
software (IBM Corp).First the normality distribution of the data was tested by Sapiro Wilk 
test followed by a Student t-test. 
In the course of the morphological analysis the signs of apoptotic, necrotic and autophagic 
cell death were taken into consideration. 
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5.4. Molecular analysis 
To assess the early (4 h post-treatment) mRNA based molecular changes of the mEHT 
induced tumor damage a human genome expression array was used. To determine the form 
of cell death and the stress related tumor response first as a screening method an apoptosis 
array was applied followed by verifying the molecular changes using 
immunohistochemistry, immunofluorescence, TUNEL assay and western blot. 
 
5.4.1. mRNA chip analysis 
To determine the early treatment related mRNA changes mRNA chip analysis was carried 
out in 9 tumor samples. 
 
5.4.1.1.Total RNA isolation and RNA quality control 
Frozen tissue sections were prepared both from the 3 treated and the 3 untreated samples 
collected at 4 h post-treatment and from the 24 h 3 sham treated controls. Total RNA was 
extracted by Roche MagNA Pure LC RNA Isolation Tissue Kit (Roche, Basel, 
Switzerland). RNA concentration was measured by NanoDrop instrument (Thermo 
Scientific, Rockford, IL, USA). The quality of the nucleic acid was determined with 
microcapillary electrophoresis system using Agilent BioAnalyzer 6000 Pico LabChip kit 
(Aligent Technologies, Santa Clara, CA, USA). With RNA Integrity Number above 7 (RIN 
> 7) 100 ng total RNA from each sample were mixed and 250 ng pooled total RNA was 
amplified and labeled in each group. 
 
5.4.1.2.Microarray analysis 
The recommendation of Minimum Information About a Microarray Experiment (MIAME) 
guideline was followed (Brazma et al. 2001). Amplification and labeling of the transcripts 
was performed by using Affymetrix 3’ IVT Express Kit (Affymetrix, Santa Clara, CA, 
USA). Samples were hybridized on HGU133 Plus2.0 arrays (Affymetrix) at 45 °C for 16 h. 
The microarrays were washed and stained on Fluidics Station 450 device (Affymetrix) 
using the vendors kit with the FS450_001 wash protocol. Fluorescent signals were detected 
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by Gene Chip Scanner 3000 (Affymetrix) following the antibody-based signal 
amplification with streptavidin-phycoerythrin according to manufacturer’s instructions.  
From the CEL files quality control and RNA digestion plots were generated in R-
environment using the Bioconductor system. The differentially expressed genes between 
the analyzed sample groups were determined by SAM (Significance Analysis of 
Microarrays) at the significance level p < 0.05. Feature selections were done according to 
the log2FC (log2 fold change) values to select at least two-fold up/downregulated genes. 
 
5.4.2. Apoptosis protein array 
To screen the apoptosis related protein changes, tissue lysates were prepared from the 
whole tumor sections of the 8, 14 and 24 h treated and 24 h sham treated control samples. 
Proteins were isolated from the frozen samples using extraction buffer (20 mM Tris, 2 mM 
EDTA, 150 mM NaCl, 1% Triton-X100, 10 µl/ml phosphatase inhibitor and 5 µl/ml 
proteinase inhibitors) for 30 min on ice, followed by centrifugation at 15,000 rpm at 4 °C 
for 15 min. Protein concentration was measured with Bradford assay the lysates protein 
concentration was set to 100 µg/µl. The expression of 35 apoptosis-related proteins was 
tested simultaneously in the treated and untreated samples using a nitrocellulose membrane 
Proteome Profiler 
TM
 Human Apoptosis Array Kit array (R&D, Minneapolis, MN). Arrays 
were incubated on a shaker with 250 µl of 1,200 µg/ml protein lysates at 4 °C overnight, 
then with biotinylated anti-human IgG for 60 min and Streptavidin-horseradish peroxidase 
(HRP) conjugate for 30 min and visualized using a chemilunescence (ECL) kit 
(SuperSignal® West Pico Chemiluminescent Kit; Thermo Sci., Rockford, IL) for 10 min in 
Kodak Image Station 4000 mm (Rochester, NY). Semi-quantitative analysis of signal 
density was done using ImageJ 1.45s (http://rsbweb.nih.gov/ij/). 
 
5.4.3. Immunohistochemistry and immunofluorescence 
All 76 FFPE tissue samples were used for creating tissue microarray (TMA) blocks to 
further characterize the proteins –and their subcellular distribution- related to mEHT 
induced cell death and cellular stress. TMAs included 3 cores of 2 mm diameter from, 2 
from the edges of degraded and intact tumor border and 1 from the degraded center, of each 
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archived tissue using the semi-automated TMA Master (3DHISTECH Ltd., Budapest, 
Hungary) (Figure 3B). For immunohistochemistry 4 m thick sections were dewaxed and 
rehydrated routinely, and then endogen peroxidase enzymes were blocked using 3% 
hydrogen peroxide in methanol for 20 min except for immunfuorescence. Antigen retrieval 
was performed either in electric pressure cooker (Avair Ida YDB50-90D, Biatlon kft, Pécs) 
at ~105°C for 50 min or in a microwave oven (Whirlpool, Benton Harbor, MI) ~100oC for 
40 min by using buffer made either of 0.01 M sodium citrate-citric acid (citrate, pH 6.0) or 
0.1 M Trisbase and 0.01 M EDTA (T-E, pH 9.0). For blocking non-specific tissue binding 
of antibodies a buffer containing 1% bovine serum albumin (BSA) and 0.1% sodium azide 
(Sigma Aldrich, St Luis, MO) was used for 20 min. Then, sections were incubated in 
humidity chambers at room temperature for 16 h using the primary antibodies listed in 
Table 1. For immunohistochemistry the EnVision polymer peroxidase detection system 
(DAKO) was used for 30 min followed by enzyme development for 5-8 min under 
microscopic control using either 3,3’-diaminobenzidine (DAB, brown) kit (RE7105, Leica-
NovoCastra, Newcastle, UK) or aminoethylcarbazole (AEC, red) kit (Dako, K3461). For 
immunofluorescence detection either Alexa546 (orange-red) or Alexa488 (green, both from 
Invitrogen-Molecular Probes) anti-rabbit Ig-s diluted in 1:200 were used for 90 min. 
Between incubations the slides were washed in Tris-buffered saline (TBS) buffer for 3x2 
min and finally counterstained using hematoxylin or 4’,6-diamidino-2-phenylindole (DAPI, 
Invitrogen-Molecular Probes). For membrane staining wheat germ agglutinin conjugated 
with Alexa488 (WGA, Invitrogen-Molecular Probes) was used.  
Biomarker expression revealed by immunofluorescence was evaluated using image (color, 
intensity and size) segmentation based software HistoQuant (3DHISTECH). 3-5 
representative annotations per tumor section involving >1000 cells each were tested. 
Relative mask area (rMA) was calculated by dividing stained area with the whole 
annotation area in the following reactions: Bax, cleaved caspasase 3, TRAIL-R2, HMGB1, 
Hsp70 and Hsp90. In the rest of detected markers, nuclear, mitochondrial or cell membrane 
signals were counted in 10 (FOV) in each core at x100 magnification. Analyzing a single 
time point, normality of the data was tested by Sapiro-Wilk test than in case of normal 
distribution the Student t-test (independent) was applied, in case of non-normal distribution 
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the Mann-Whitney U-test was used. To analyze time series, we used the Friedmann test 
followed by the Wilcoxon post-hoc test. The results were significant at p < 0.05. For all 
statistical analysis the SPSS software (SPSS Statistics v.20; IBM, New York, NY) was 
used. 
 
Table 1. Antibodies and conditions used for immunohistochemistry and immuno-
fluorescence. 
Antigen Clonality Host Dilution Vendor 
Antigen 
retrival 
AIF polyclonal rabbit 1:25 Cell Signaling T-E 
Bax polyclonal rabbit 1:50 
Sigma 
Aldrich 
T-E 
cleaved 
caspase-3 
polyclonal rabbit 1:100 Cell Signaling citrate 
cytochrome c polyclonal rabbit 1:50 Cell Signaling T-E 
mitochondrial 
antigen 
monoclonal 
(113-1) 
mouse 1:50 
BioGenex 
Laboratories 
T-E 
RIP1 
monoclonal 
(D94C12) 
 rabbit 1:100 Cell Signaling T-E 
RIP3 polyclonal rabbit 1:400 
Sigma 
Aldrich 
T-E 
TRAIL-R2 
monoclonal 
(D4E9) 
rabbit 1:50 Cell Signaling T-E 
Ki-67 
monoclonal 
(SP6) 
rabbit 1:600 LabVision T-E 
calreticulin polyclonal rabbit 1:100 Cell Signaling T-E 
HMGB1 polyclonal rabbit 1:200 Cell Signaling T-E 
Hsp70 polyclonal rabbit 1:50 Cell Signaling T-E 
Hsp90 polyclonal rabbit 1:100 Cell Signaling T-E 
CD3 polyclonal rabbit 1:2 DAKO T-E 
MPO polyclonal rabbit 1:200 
Sigma 
Aldrich 
citrate 
Vendor specification: Sigma Aldrich, ST Luis, MO; Cell Signaling, Danvers, MA; 
LabVision Thermo Sci, Rockford, IL; BioGenex Laboratories, San Ramon, CA. 
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5.4.4. Terminal deoxynucleotidyl transferase nick end labeling (TUNEL) 
assay 
TUNEL assay was used to pre-screen FFPE TMA sections for DNA fragmentation 
including the whole time-lapse series of mEHT treated, untreated and sham treated control 
xenografts. Based on the semi-quantitative results the assay was also performed on whole 
cross sections of mEHT treated tumors and their matched untreated pairs of 24h and 48h 
post-treatment. TUNEL assay is based on the detection of DNA nick ends by terminal 
deoxynucleotidyl transferase (TdT) and linking them with fluorochome labeled 
deoxyuridine triphosphate (dUTP) nucleotides by the TdT enzyme. Labeling in cell nuclei 
is proportional to the amount of fragmented DNA as a result of programmed cell death. The 
“Click it TUNEL Alexa Fluor 488 Imaging Assay” (Invitrogen) was used according to the 
manufacturer’s instructions. Briefly, dewaxed and rehydrated slides were heated in a citrate 
based pH 6.0 antigen unmasking solution (H-3300, Vector Lab, Burlingame, CA) using 
electric pressure cooker (Avair Ida, as above). Then slides were incubated at 37 °C for 
60 min with a cocktail of alkyne substituted dUTP and TdT followed by the fluorochrome 
for 30 min at room temperature which is coupled to dUTP under copper (I) catalysis. 
Finally, nuclear DNA was stained with DAPI (see above). The number of biomarker 
positive cells was counted at x100 objective magnification in 10 different microscopic FOV 
of 3 treated and 3 untreated samples at each tested time point. DAPI co-staining was used 
for confirming the critical nuclear localization in the samples. The data was first tested by 
Kolmogorov-Smirnov normality test followed by the independent t-test (SPSS Statistics 
v.20; IBM, New York, NY). 
 
5.4.5. Western blot 
Tissue lysates were prepared from 4, 14 and 24 h treated, untreated and 24 h sham treated 
control frozen samples to measure expression of proteins characteristic to programmed cell 
death. Extraction buffer (20 mM Tris, 2 mM EDTA, 150 mM NaCl, 1% Triton-X100, 
10 µl/ml phosphatase inhibitor and 5 µl/ml proteinase inhibitors) for 30 min on ice were 
used to produce tissue lysates, followed by centrifugation at 15,000 rpm at 4 °C for 15 min. 
Protein concentration was measured with Bradford assay. The extracts were mixed with 5x 
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Laemmli sample buffer containing 5% 2-mercaptoethanol and heated to 95 °C for 5 min. 
30 g protein was loaded into each well of 12% sodium dodecylsulfate polyacrylamide gel 
(SDS-PAGE) and electrophoresis was done at 150 V for 1 h. Proteins were then 
immunoblotted into polyvinylidene difluoride (PVDF) membrane at 75 mA and 4 °C 
overnight. For immunodetection, membranes were sequentially incubated with 5% semi-
skimmed milk as a protein block for 60 min, followed by the incubation with primary 
antibody (Table 2) at 4 °C and (HRP)-conjugated goat anti-rabbit IgG (1:1000; Cell 
Signaling) for 60 min and SuperSignal ECL kit (Thermo Sci.) for 10 min. For loading 
control β-actin (1:500, Cell Signaling) was used. The precision Plus Protein Standard 
ladder produced bands at 250kDa, 150-, 100-, 75-, 50-, and 37kDa. Signals were detected 
using Kodak Image Station and its 4.1 software. All reagents except where otherwise 
indicated were from BioRad (Hercules, CA). Semi-quantitative analysis was done using 
ImageJ 1.45s software (http://rsbweb.nih.gov/ij/). 
 
Table 2. Antibodies and condition used for Western immunoblots 
Antigen Clonality Host Dilution Vendor 
caspase-3 polyclonal rabbit 1:1000 Cell Signaling 
caspase-8 polyclonal rabbit 1:2000 Sigma Aldrich 
AIF polyclonal rabbit 1:1000 Cell Signaling 
RIP1 polyclonal rabbit 1:1000 Sigma Aldrich 
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6. RESULTS 
 
6.1. Histomorphological analysis of treatment related tumor cell death 
The H&E stained cross sections of HT29 xenografts showed significant damaged central 
zones of the treated tumors between 24-120 h post-treatment, which were clearly 
demarcated as pale areas (Figure 3A). At this stage we did not discriminate among the 
different types of cell death subroutines. Free annotation option within the digital slide 
viewer software allowed accurate area measurements in m2. Damaged areas were 
correlated with the whole tumor area (TDR) (Figure 4A). When TDR values of treated and 
untreated tumors were compared the mEHT related cell destruction (TDE) was not 
significantly changed within the first 14 h post-treatment but it showed a dynamic increase 
between 14-24 h. The peak of a single shot treatment showed a 7-fold increase in cell 
damage 72 h after mEHT treatment (Figure 4B), which was gradually reduced between 
120 h and 216 h.  
H&E slides were lack of any morphological sign of autophagic cell death. 
 
 
Figure 4. Measurement of mEHT related tumor destruction. A) The TDR (tumor 
destruction ratio) upon mEHT treatment significantly exceeded that measured in the 
untreated tumors from 24h post-treatment on. B) The TDE (tumor destruction efficiency) 
values, which exclude the systemic effect of mEHT treatment, also show treatment related 
increase with a peak at 72 h post-treatment. 
 
DOI:10.14753/SE.2015.1802
36 
 
6.2. Detection of treatment related DNA fragmentation 
TUNEL assay utilizing nick end labeling of damaged and fragmented DNA with 
fluorescent labeled dUTP was performed in the HT29 xenograft tumors. First, the kinetics 
of DNA damage was pretested in TMA sections for selecting the most appropriate time 
points for detailed analysis (χ2(11) = 26.931, p < 0.05). The TUNEL assay proved 
significantly higher programmed cell death related DNA fragmentation in whole cross 
sections of the treated compared to the untreated tumors both at 24 h and 48 h post-
treatment (Figure 5A, B). In agreement with this, there was a significantly higher degree of 
nuclear shrinking (pycnosis) and accumulation of dense chromatin fragments (apoptotic 
bodies) in the treated compared to the untreated tumors with a peak difference reached at 
72 h, as counted at high power (x100) microscopic fields of H&E stained slides 
(Figure 5A, C). 
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Figure 5 showing DNA fragmentation, nuclear shrinkage and apoptotic bodies. A) 
Significant elevation of DNA fragmentation revealed by TUNEL assay (green 
fluorescence), nuclear shrinkage and apoptotic bodies (H&E staining; arrows) in mEHT 
treated (upper row) compared to untreated tumors (lower row), at 48h post-treatment. Insets 
show single channel views of areas within rectangles at higher power. TUNEL and DAPI 
(blue) double positivity verifies nuclear DNA staining in identical cells labeled. Untreated 
tumor cells show only basic green fluorescence. Bar indicates 50 m in the left column and 
15 m in the right column. B) Graphs showing significantly increased mean number of 
TUNEL positive cells both at 24 h and 48 h post-treatment (black columns); and C) of 
apoptotic bodies at 48 h and 72 h post-treatment (black columns) compared to the untreated 
controls (grey columns) (*p < 0.05, **p < 0.01). 
 
6.3. Detection of treatment related differential mRNA expression  
Messenger RNA gene expression was measured from pooled samples of the 4 h treated, 4 h 
untreated and 24 h sham treated tumors, respectively using Affymetrix HGU133 Plus2.0 
mircoarrays. Modulated EHT treatment induced significant up- or down-regulation of 48 
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transcripts of 39 genes compared to controls. Members of the heat shock protein 70 family 
including HSPA1A, HSPA1B, HSPA4, HSPA6 and HSPA8, and their co-chaperons hsp40 
(DNAJB1 and DNAJB4) and Bag3 became upregulated. Hsp90 alpha (HSP90AA1) and 
hsp60 (HSPD1) gene transcripts were also elevated upon mEHT treatment (Figure 6). 
 
 
Figure 6. Heat map on gene expression summarizing transcripts showing significantly 
differential expression 4 h after mEHT treatment of HT29 colon cancer xenografts. 
Arrows highlight the elevated expression (red boxes) of heat shock protein genes from the 
Hsp70, Hsp40, Hsp90 and Hsp60 families in the treated samples (left column) compared 
either to sham treated (middle) and untreated samples (right). 
 
6.4. Detection of apoptosis related differential protein expression 
The expression of 35 apoptosis related proteins was compared using pooled samples of 3 
animals at each time point from treated (8, 14 and 24 h post-treatment) and sham treated 
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(24 h post-treatment) experiments on nitrocellulose membrane plotted protein arrays. 
Protein extraction was made using whole cross sections of the dissected frozen tumors.  
We detected the early (8h post-treatment) elevation of 12 apoptosis related proteins 
including Bax, catalase, c-IAP, cytochrome c, TRAIL-R2, FADD, Hsp60, Hsp70, Hsp27, 
HTRA2/Omi, HO-2, SMAC/Diablo (Figure 7). Due to the cell death related progressive 
inhomogenity of treated tissues observed at morphological analysis, only the 8 h post-
treatment samples were considered representative. 
 
 
Figure 7. Modulated EHT induced elevated expression of apoptosis related proteins. 
Elevated expression of A) Bax, B) FADD, C) Hsp60, D) cytochrome c, E) SMAC/Diablo 
F) HTRA2/Omi and G) hsp70 proteins upon mEHT treatment of HT29 xenograft tumors in 
apoptosis protein arrays. 
 
No significant change in the expression of Bad, pro-Caspase-3 and cleaved Caspase-3 
proteins were detected between the treated and the control samples (Figure 8) 
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Figure 8. Unchanged expression of apoptosis related proteins upon mEHT. Unchanged 
expression of A) Bad, B) procaspase-3 (casp-3) and C) cleaved caspase-3 (c-casp-3) 
proteins upon mEHT treatment of HT29 xenograft tumors in apoptosis protein arrays. 
 
The mEHT treatment resulted in the reduced expression of 5 apoptosis related proteins 
including Fas, phospho-p53 (S392), phosphor-p53 (S15) Survivin and XIAP. (Figure 9)  
 
 
Figure 9. Reduced expression of apoptosis related proteins upon mEHT. Reduced 
expression of A) Fas, B) Survivin and C) XIAP proteins upon mEHT treatment of HT29 
xenograft tumors in apoptosis protein arrays. 
 
No signal was detected in case of the following proteins: BAD, Bcl-2, Bcl-x, cIAP2, 
claspin, clusterin, TRAIL-R1, Hif-1a, HO1, Livin, PON2, p21, p53(S46), pRad17 and 
TNFRSF1A. 
The expression and subcellular localization of Bax, cleaved Caspase-3, cytochrome c, 
TRAIL-R2 and Hsp70 proteins were further tested in situ in tissue sections using 
immunohistochemistry or immunofluorescence technique.  
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6.5. Detection of treatment related differential protein expression in situ 
6.5.1. Programmed cell death related proteins 
TMA sections prepared from HT29 xenograft tumor samples were immunostained using 
antibodies recognizing the following programmed cell death and proliferation related 
protein antigens: AIF, Bax, cleaved Caspase-3, Cytochrome c, RIP1, RIP3, TRAIL-R2 and 
Ki67. 
Modulated EHT treatment resulted in the significant mitochondrial accumulation of Bax 
protein and the mitochondrial to cytoplasmic release of cytochrome c protein both at 8 h 
(*p < 0.05) and 14 h (**p < 0.01) post-treatment. Mitochondrial localization of these pro-
apoptotic proteins was confirmed using double immunofluorescence staining for either of 
these proteins and anti-mitochondrial antigen (Figure 10).  
Treatment related significant cytoplasmic to nuclear translocation of the AIF protein was 
observed both at 14 h (*p < 0.05) and 24 h (**p < 0.01) post-treatment (Figure 11A, B) as 
an effector for DNA fragmentation. As opposed to this, normal cytoplasmic granular 
(mitochondrial) expression of AIF was seen in the intact tumor cells and in cells of the 
reactive microenvironment. Also AIF western immunoblots confirmed the mitochondrial 
62 kDa band in both treated and untreated samples and the 57 kDa band corresponding to 
the molecular range of released protein from the mitochondria in the treated samples 14 h 
post-treatment (Figure 11C). 
Though a significant elevation in the effector cleaved Caspase-3 levels was observed in the 
mEHT treated tumors compared to their untreated controls (*p < 0.05) at 4 and 8 h post-
treatment, the signals were detected only at a very low level resulting in an undetectable 
global difference in Western immunoblots between treated and control samples. 
Furthermore, the cleaved Caspase-3 reaction was almost exclusively localised to 
inflammatory cells involving myeloperoxidase positive neutrophil granulocytes 
(monocytes) and CD3 positive immature T lymphocytes demarcating the cleaved 
Caspase-3 negative tumor nests (Figure 12). 
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Figure 10. Immunofluorescence staining (Alexa 564, red) for the pro-apoptotic Bax 
and cytochrome c (cyt c) proteins and semi quantitative image analysis of the signals 
in mEHT treated and untreated tumors. A) Mitochondrial accumulation of Bax and 
cytoplasmic release of cytochrome c (cyt c) are linked with the mEHT treatment at 14 h. 
Insets highlight areas in rectangles at high power (arrows, x100) where cytoplasmic 
delocalization of cyt c in the treated tumor is shown by arrows. Cell nuclei are stained using 
DAPI (blue). Identical sections labeled for cyt c were later stained also for H&E where 
circled area reveals pyknotic tumor cell nuclei. B) Mitochondrial localization of Bax in the 
treated and cyt c (both red) in the untreated samples was confirmed by their co-localization 
with anti-mitochondrial antigen (mito - green). Bar indicates 25 μm in the insets and 60 μm 
in the rest of 4A and 10μm in 4B. C) Graphs showing significant increase of accumulated 
granular Bax reaction in tumor cells (*p < 0.05; **p < 0.01) (rMA- relative mask area) and 
D) loss of granular cyt c reaction (black columns) upon mEHT treatment compared to 
untreated controls (grey columns) (FOV- field of views).  
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Figure 11.  Activation of apoptosis inducing factor (AIF) upon mEHT treatment of 
HT29 xenografts. A) Identical tissue sections consecutively stained for AIF using 
immunofluorescence (Alexa 564, red) then with H&E. Many tumor cells show nuclear 
translocation of AIF in the treated but not in the untreated tumors. Insets show single 
channel views at higher power of representative areas within rectangles. Arrows highlight 
identical cells with nuclear AIF staining. Arrowheads points to tumor nests of granular 
mitochondrial AIF staining characteristic of intact tumor cells. Cell nuclei are stained using 
DAPI (blue). Bar indicates 50 µm in the left and 25 µm in the right column. B) Graph 
showing the significantly elevated mean number of nuclear AIF positive cells in the treated 
(black columns) compared to the untreated (grey columns) tumors (*p < 0.05; **p < 0.001). 
C) In western immunoblots the 57 kDa cleaved AIF protein is detected only in the treated 
tumors at 14 h post-treatment besides the mature 62 kDa protein. 
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Figure 12. Expression of caspase-3 protein in mEHT treated HT29 xenografts. A) 
Though treated tumors show significantly more cleaved/activated caspase-3 (C casp-3) 
positive cells than untreated controls (left column; AEC, red), the reaction is primarily 
localized to peritumoral leukocytes (arrows) and not to tumor nests (asterisks). Bar 
indicates 50 m in the left and 25 m in the right columns. B) Cleaved caspase-3 positive 
areas (relative mask area; rMA) measured with the HistoQuant software are significantly 
higher (*p < 0.05) in the treated than in the untreated samples both at 4 h and 8 h post-
treatment. C) Caspase-3 expression (either the full length 32 kDa or the missing 17 kDa 
cleaved fragment) does not differ significantly in the treated compared to the untreated 
tumors. The 17 kDa fragment is detected in Staurosporine treated control HTC-116 cell 
extract.  
 
Based on the apoptosis array results, which revealed an elevated TRAIL-R2 expression in 
the treated compared to the untreated samples, immunofluorescence staining also showed a 
highly significant elevation (**p < 0.01) of TRAIL-R2 protein levels in the mEHT treated 
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compared with the control samples both at 8 h and 14 h post-treatment using automated 
image analysis based on signal intensity segmentation and area measurement (Figure 13). 
Furthermore, there was no significant change in RIP protein levels (neither in RIP1 nor in 
RIP3) upon mEHT treatment. RIP kinase could have mediated necroptosis, another caspase 
independent form of programmed cell death, either using RIP1 or RIP3.  
There was no significant change in caspse-8 expression either on immunostaining or on 
western blot where the cleaved fragment was not detected at any time point. 
Ki67 immunostaining also revealed no significant difference in cell proliferation at any 
time point in the morphologically intact tumor areas between the mEHT treated and control 
samples, while the staining was lost from 24h post-treatment on in the destructed areas 
(data not shown). 
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Figure 13. Significant upregulation of TRAIL-R2 cell membrane death receptor upon 
mEHT treatment of HT29 xenografts. A) Image analysis using the HistoQuant software 
confirms the significantly elevated expression of TRAIL-R2 protein both 8h and 14h post 
treatment (black columns) compared to the untreated tumors (grey columns). B) An 
immunopositive (Alexa564, red fluorescence) area (left) thresholded and masked (right) for 
defining the relative mask area (rMA = masked/annotated area). C) Elevated expression of 
TRAIL-R2 protein in the tumor cell membranes (red) both 8h and 14h post-treatment 
compared to the untreated tumors of the opposite legs. Please note that TRAIL-R2 
expression is evenly widespread at 8h but only focal at 14h and show lower levels towards 
the tumor centre (asterisk) in line with the progressing tumor damage. Insets show higher 
power views of representative tumor areas within dashed rectangles. Cell nuclei are stained 
using DAPI (blue). 
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6.5.2. Stress related proteins 
TMA samples from the HT29 xenograft experiment were stained using the following 
antibodies recognizing stress related proteins: CRT, HMGB1, Hsp70 and Hsp90.  
Immunofluorescence analysis revealed elevated expression of Hsp70 between the treated 
and untreated group (χ2(19) = 54.634, p < 0.05). The post-hoc test showed significant 
difference between 14-24 h and 72-120 h post-treatment and a transitional decrement at 
48 h. At 14h post-treatment the association of Hsp70 to the cytoplasmic membrane was 
significant in the treated xenografts. At later (72-120 h) stages no cytoplasmic membrane 
positivity was seen however, upregulation of cytoplasmic Hsp70 was observed, but only in 
the transient zone between the morphologically intact and dead tumor areas (Figure 14). 
Also, significantly increased Hsp90 levels were detected (χ2(21) = 83.559, p < 0.05) in the 
mEHT treated compared to the untreated tumors, at 24, 48, 72, 120, 168 and 216 h after 
mEHT treatment as revealed by the post-hoc test (Figure 15). Hsp90 appeared in the 
cytoplasmic membrane only at later time points at 168 h and 216 h post-treatment. In 
contrast to Hsp70 kinetics, Hsp90 levels showed continuous elevation upon treatment 
between 24 h and 216 h.  
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Figure 14. Abundance and 
localization of heat shock 
protein 70 (Hsp70) in colorectal 
cancer xenografts measured 
with immunofluorescence 
(Alexa 564, red). A) Hsp70 
immunofluorescence (Alexa 564, 
red), in 14 h post-mEHT treated 
(a-e) and untreated (f-j) tumor 
cells also immunoreacted with 
wheat germ agglutinin (Alexa 
488, green) and DAPI to stain 
nuclei. In 14 h post-mEHT treated 
tumor cells Hsp70 
immunofluorescence is 
predominately in cell membranes 
(arrows) as indicated by the wheat 
germ agglutinin reactivity 
(arrowheads). In the untreated 
tumor cells Hsp70 
immunofluorescence is 
predominately cytoplasmic. Scale 
bar = 80 µm in a and f, 10 µm in b 
and g, and 5 µm in c, d, e and h, i, 
j. B) Semi-quantitative image 
analysis of immunofluorescence 
confirms significant elevation of 
Hsp70 levels both between 
14-24 h and 72-120 h post-
treatment (*p < 0.05) with a 
decline at 48 h (rMA- relative 
mask area). 
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Figure 15. Heat shock protein 90 (Hsp90) immunofluorescence (Alexa 564, red) and 
semi-quantitative analysis of Hsp90 in post-mEHT treated and untreated colorectal 
cancer xenografts. A) Hsp90 immunofluorescence is predominately cytoplasmic at 24 h 
(a) and associated with cell membranes at 168 h post-mEHT (b; arrows), and as shown in 
the inset. Hsp90 immunofluorescence is less apparent at 24 h (c) and at 168 h (d) in 
untreated tumor cells. Cell nuclei are stained blue (DAPI). Scale bar = 60 µm in all and 
20 µm in the inset. B) Graph showing significant increase of Hsp90 protein between 
24-216 h in the treated compared to the untreated tumor cells in the morphologically intact 
tumor areas (*p < 0.05) (rMA- relative mask area). 
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Furthermore, the early accumulation of calreticulin to the cell membrane, before any 
morphological or molecular sign of programmed cell death, was observed at 4 h (p = 0.001) 
post-treatment (Figure 16). 
 
 
Figure 16. Calreticulin immunofluorescence (Alexa 564, red) and semi-quantitative 
analysis of calreticulin in post-mEHT treated and untreated colorectal cancer 
xenografts. A) Calreticulin immunofluorescence is localized to the cell membranes 4 h 
post-mEHT (arrows; a - e) before any morphological or molecular sign of programmed cell 
death. Calreticulin immunofluorescence is diffuse and cytoplasmic in untreated tumor cells 
(f - j). Cells nuclei are stained blue (DAPI). Scale bar = 60 µm in a, b, c, f, g, h and 10 µm 
in d, e, i, j. B) Graph showing the mean number of cytoplasmic membrane positive cells 
counted at x 100 magnification in 10 field of views (FOV) of 5 parallel samples. Elevation 
of calreticulin cell membrane immunofluorescence is highly significant (**p < 0.01) in 4 h 
post-mEHT treated compared to untreated tumor cells (FOV- field of views). 
 
HMGB1 protein was detected in cell nuclei up to 14 h both in the treated and in the 
untreated samples, followed by a cytoplasmic translocation from 24 h in the treated 
xenografts. HMGB1 immunofluorescence disappeared 48 h post-treatment from the 
damaged central areas of the treated tumors while still prevailed in the untreated controls.  
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Figure 17. HMGB1 immunofluorescence (Alexa 564, red) and semi-quantitative 
analysis of HMGB1 post-mEHT treated and untreated colorectal cancer xenografts. 
A) HMGB1 immunofluorescence shows normal nuclear localization up to 14 h post-mEHT 
treated (a) and untreated (d) tumor cells. HMGB1 immunofluorescence is diffuse and 
diminished in 24 h and not evident in 48 h post-mEHT treated (b, c, respectively) tumor 
cells but not changed in 24 and 48 h untreated (e, f, respectively) tumor cells. Boxes show 
the location of the high magnification insets. Circles in the insets show the location of 
nuclei. Scale bar = 60 µm in a, b, c, d, e, f, and 25 µm in all insets. B) Semi-quantitative 
analysis highlights significant reduction of HMGB1 immunofluorescence between 48-216h 
post mEHT treated compared to untreated tumor cells (*p < 0.05) (rMA- relative mask 
area). 
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In the treated tumors nuclear HMGB1 protein was significantly lost (χ2(19) = 64.657, 
p < 0.05) compared to the untreated group, post-hoc test revealed significant difference at 
each time point between 24-216 h post-treatment (Figure 17). 
 
6.5.3. Identification of immune cells 
TMA samples from the HT29 xenograft experiment were also stained for CD3 and MPO 
antigens to identify major subgroups of leucocytes. The results revealed that though 
BALB/c (nu/nu) mice have compromised immune system featuring deficient thymic 
functions and T cell maturation a massive inflammatory infiltrate was observed in the 
treated tumors, which was concentrated at the boundary of degraded and intact tumor. The 
number of MPO positive neutrophil granulocytes (and monocytes) were significantly 
elevated in the treated samples (χ2(21) = 51.364, p < 0.05) compared to the controls. The 
post-hoc test confirmed the significant elevation at 48, 72, 120, 168 and 216 h post-
treatment. The number of CD3 positive immature T lymphocytes was also significantly 
higher in the treated group (χ2(21) = 79.949, p < 0.05) than in the controls. The difference 
was proved significant at 120, 168 and 216 h post-treatment (Figure 18). 
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Figure 18. Leukocyte infiltration detected with immunohistochemistry upon mEHT 
treatment of HT29 colorectal cancer xenografts. A-B) The number of both the 
myeloperoxidase (MPO - red) positive neutrophil granulocytes (A) and the CD3 positive 
(brown) T lymphocytes (B) are significantly elevated in the treated compared to the 
untreated tumors at 72 h (only for MPO) and 120 h (both markers) post-treatment. C-D) 
Graphs show the dynamic treatment related appearance of MPO positive cells (C) and CD3 
positive cells (D) during the study period. Peritumoral infiltration by myeloid leukocytes 
(C) start very early (after 1h), while T cell accumulation is observed after 72 h and both 
show significant treatment related elevation afterwards. Black boxes represent the mean 
scores in the treated tumors and grey boxes highlight scores gained in the untreated 
controls. Red triangles show leukocyte scores in xenografts of sham-treated animals. 
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7. DISCUSSION 
 
Electric field and the concomitant heat induced by modulated electrohyperthermia (mEHT) 
can be selectively enriched in malignant tissue due to elevated glycolysis (Warburg effect), 
ion concentration and the resulting elevated conductivity and permittivity in cancer 
compared to non-malignant tissues. The objective of this study was to investigate the nature 
and time course of tumor cell destruction, its molecular mechanism and the stress-related 
molecular changes induced by mEHT in HT29 colorectal cancer xenograft model.  
Modulated EHT is a non-invasive technique in oncotherapy using 13.56 MHz capacitive 
coupled radiofrequency field. The generated electric field selectively enriches in the 
malignant tumor tissue due to the bioelectrodynamic differences (such as elevated 
permittivity and conductivity) related to metabolic (Warburg-effect and the concomitant 
elevation in ion concentration) and structural differences (such as increased water and 
sodium content and altered membrane permeability) compared to non-malignant tissue 
(Pethig et al. 1984; Scholoz et al. 2000; Andocs et al. 2009). Our results in this project are 
based on morphological observations, mRNA expression microarray studies, in vitro 
(protein array chip and Western immunoblot) and in situ (immunoperoxidase and 
immunofluorescence) protein detection studies combined with digital microscopy based 
semiquantitative image analysis and the TUNEL assay. 
Comparative analysis of hematoxylin and eosin stained sections across the center of tumor 
xenografts revealed significant tumor destruction between 24-120 h after a 30 min long 
single shot of mEHT treatment. At this stage, we did not discriminate between the different 
types of cell death subroutines (apoptosis, necroptosis, accidental necrosis, autophagia, etc). 
The peak of tumor destruction reached a 7-fold increase at 72 h post-treatment compared to 
the untreated contralateral xenograft. Significant appearance of apoptotic bodies were 
observed 48-72 h post-treatment, and TUNEL positivity, referring to DNA fragmentation, 
was found the highest at 24-48 h post-treatment. Chromatin condensation, the appearance 
of discrete nuclear bodies and the signs of the DNA fragmentation together suggested 
programmed cell death (Kroemer et al. 2009) as the major mechanism of tumor destruction 
upon mEHT treatment. Hyperthermia was described to be suitable to induce both accidental 
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necrosis and programmed cell death in vitro in a temperature dependent manner without 
specifying the dose related response (Hildebrandt et al. 2002). Most of the apoptotic cell 
death inducing treatments were achieved in hematological cell lines (Harmon et al. 1990; 
Baxter et al. 1992; Gabai et al. 1995) which are known to be rather thermo-sensitive 
(Hildebrandt et al. 2002). In these studies the molecular mechanism of cell death was not 
described in details, and the results were rather contradictory. As opposed to our findings, 
in vitro hyperthermia delivered in a 42 °C incubator or in a water bath, could not induce 
DNA fragmentation in HT29 colorectal carcinoma cells up to 72 h post-treatment (Nishida 
et al. 1997; Shchepotin et al. 1997). 
Because both the morphological and molecular signs suggested DNA fragmentation and 
programmed cell death mechanisms we have tested molecules that might be involved and 
characteristic of the major programmed cell death pathways. The mitochondrial 
accumulation of pro-apoptotic Bcl-2 superfamily member Bax was found to be significant 
between 8-14 h post-treatment in the treated tumors compared to the contralateral untreated 
xenografts. In line with the morphological findings, mitochondrial Bax was consistent with 
a controlled outer mitochondrial membrane pore formation, which further supported the 
programmed nature of the treatment induced cell death (Gogvadze et al. 2006; Basanez et 
al. 2012; Galluzzi et al. 2012). Due to the mitochondrial pores intermembrane space 
proteins can also be released from the mitochondria (Tait et al. 2010). Accordingly, 
significant mitochondrial to cytoplasmic cytochrome c release was observed between 
8-14 h post-treatment, simultaneously with mitochondrial Bax accumulation, reflecting the 
rapid cytoplasmic release of cytochrome c (Basanez et al. 2012). At 8 h post-treatment 
elevated expression of the intermembrane space proteins Smac/Diablo and HTRA2/Omi 
were also detected, as a further support of the cytoplasmic release of intermembrane space 
proteins (Tait et al. 2010). Mitochondrial pore formation, and concomitant loss of 
mitochondrial transmembrane potential, together with the release of intermembrane space 
proteins to the cytoplasm can lead to an irreversible “point of no return” in the fate of 
affected cells (Kroemer et al. 2005; Kroemer et al. 2009). Between 14-24 h post-treatment 
mitochondrial AIF was released to the nucleus, where the 57 kDa activated AIF fragment 
was also detected using immunoblots. AIF release from the mitochondria requires a 
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cleavage in the mitochondrial intermembrane space (Norberg et al. 2010), and a 
concomitant time delay can be noted compared to the pore formation and mitochondrial 
protein release (Norberg et al. 2010). Activated nuclear AIF fragments are responsible for 
chromatin condensation and cleavage of the DNA into relatively large 50 kbp fragments 
(Boujrad et al. 2007), which were detected with the TUNEL assay at later time points. 
Modulated EHT induced programmed cell death in HT29 xenograft in a caspase 
independent manner, since cleaved caspase-3 protein was not found in the tumor cells at 
any tested time point. Although detected cleaved-caspase 3 levels were significantly higher 
in the treated whole tumor samples compared to the untreated control xenografts, 
immunohistochemistry revealed that cleaved caspase-3 positive cells were found only in 
stromal inflammatory cells adjacent to tumor nests. These cells were consistently MPO 
positive myelomonocytic cells primarily of neutrophil granulocytes and CD3 immature T 
lymphocytes (immunocompromised animals). Leukocytes are known to be sensitive for 
heat shock (Hildebrandt et al. 2002; Dieing et al. 2003), which can explain their relatively 
high cleaved caspase-3 positivity. The timing and major molecular pathways involved in 
mEHT treatment related tumor cell death are summarized in a simplified scheme in 
Figure 19. 
When markers for necroptosis (programmed necrosis) were analyzed, no significant 
difference was found at any time point either in RIP1 or RIP3 expression between treated 
and untreated tumors. RIP1 and RIP3 are crucial members of the necrosome complex 
(Vandenabeele et al. 2010), which can be activated by phosphorylation. RIP1 at Ser161 can 
be either autophosphorylated or phosphorylated by RIP3, which can also be phosphorylated 
on Ser199 for activation (Vandenabeele et al. 2010; Han et al. 2011). Although RIP3 seems 
to be necessary for regulated necrosis it can be either dependent or independent on RIP1 
(Vandenabeele et al. 2010; Han et al. 2011; Galluzzi et al. 2012). RIP1 and RIP3 can be 
inactivated by proteolytic cleavage resulting in the shifting of cell degradation pathway to 
external apoptosis. Despite the extensive research the exact downstream mechanism of 
regulated necrosis has not been clarified yet (Christofferson et al. 2010; Han et al. 2011). 
The lack of massive cytoplasmic vacuolization and the proven Bax mediated mitochondrial 
pore formation rule out the possibility of autophagic cell death (Galluzzi et al. 2012). 
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Interestingly, preliminary results of mEHT treated C26 (murine colorectal carcinoma cell 
line) allografts suggest rather a caspase dependent cell death pathway. Therefore, further 
investigations are needed for revealing the factors that determine the different programmed 
cell death subroutines. 
 
Figure 19. Schema of mEHT induced programmed cell death mechanism in HT29 
xenograft model. Treatment related mitochondrial pore formation was observed 8-14 h 
post-treatment by Bax mitochondrial localization, in line with this cytochrome c released 
from the mitochondria. Concomitant nuclear AIF induced DNA fragmentation followed by 
apoptotic body formation. 
 
As it was described earlier ICD requires a characteristic spatiotemporal emergence of a 
DAMP signal sequence including the early (pre-apoptotic) exposure of calreticulin to the 
cell surface as ecto-calreticulin, followed by a membrane localization and release of Hsp70 
and/or Hsp90 accompanied by ATP release during the programmed cell death process, the 
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late apoptotic release of HMGB1 and possible late externalization of Hsp70 and or Hsp90 
(Garg et al. 2013; Kroemer et al. 2013; Krysko et al. 2013). Different ICD inducers can 
provoke slightly distinct DAMP patterns. For example, oxaliplatin can initiate the pre-
apoptotic ecto-calreticulin exposure, followed by an early-apoptotic ATP release without 
Hsp involvement, with late apoptotic HMGB1 release (Ladoire et al. 2013). Another 
example is hypericin based photodynamic therapy, which induces pre-apoptotic ecto-
calreticulin exposure and ATP release with pre-apoptotic Hsp70 membrane appearance and 
the passive, late-apoptotic release of Hsp70, Hsp90 and HMGB1 (Garg et al. 2012; Krysko 
et al. 2012).  
In our HT29 colorectal xenograft model a significant early (4 h post-treatment) cell 
membrane exposure of calreticulin was detected in the treated compared to the contra-
lateral untreated tumors. The first molecular signs of programmed cell death were revealed 
later at 8 h post-treatment. Ecto-calreticulin can serve as an ‘eat-me’ signal which can bind 
to DCs and macrophages through CD91 to stimulate the efficient engulfing of dying cells, 
and processing their antigens followed by priming a connate immune response (Kroemer et 
al. 2013). 
Hsp70 was found in the cytoplasmic membranes of tumor cells from 14 h post-treatment 
followed by a decrement at 48 h with a second peak observed at 72 h post-treatment in the 
morphologically intact peripheral part of mEHT treated xenografts. This second peek is 
possibly related to the soluble factors released from the mEHT damaged cells. Significant 
elevation of Hsp90 was observed from 24h post-treatment but membrane association of 
Hsp90 was observed only at later time points (168-216 h). Interactions of membrane 
associated Hsp70 with immune cells can be rather complex. Membrane associated Hsp70 
combined with IL-2 and IL-15 can stimulate natural killer (NK) cells (Gehrmann et al. 
2008). Membrane bound Hsp70-peptide complex possibly bind to scavenger receptors, 
C-type lectin receptor or TLR 2/4 or a currently not well defined receptor on APCs 
including monocytes, macrophages and DC followed by cross presentation on MHC 
molecules to initiate antigen specific immune response through CD8+ T cells (Multhoff 
2007; Gehrmann et al. 2008). Extracellular Hsp70 can directly boost the innate immune 
response (Multhoff et al. 2011). However, membrane bound Hsp70 has also been described 
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to protect cell membrane integrity under stress condition (Horvath et al. 2008; Horvath et 
al. 2010), therefore, the outcome of cell membrane exposure of Hsp70 can be context 
dependent. Membrane associated Hsp90 binding receptors on APCs have not been 
identified yet (Garg et al. 2013).  
The late HMGB1 release from cell nuclei was observed from 24 h post-treatment showing 
first a cytoplasmic manifestation in the mEHT destructed central tumor areas. HMGB1 
staining was worn off between 48-216 h post-treatment. Given that HMGB1 can also be 
released passively from the necrotic cells nuclei (Guo et al. 2013), necrotic areas of 
untreated tumors also showed moderate HMGB1 disappearance. The mEHT related 
spatiotemporal appearance of DAMP signals, which can be relevant to ICD in the HT29 
xenograft model is summarized in a drawing (Figure 20). 
Earlier, HMGB1 was thought to be released only from the necrotic cells, recent evidence 
suggest that cells dying through a programmed cell death subroutine can also release 
HMGB1 (Ladoire et al. 2013). The extracellular HMGB1 can bind to RAGE, TIM3 or 
TLR2/4 on the DCs leading to distinct responses (Garg et al. 2013). HMGB1-RAGE 
interaction may mediate invasion, migration and tumor growth resulting in the association 
with aggressive tumor phenotype and poor prognosis in colon carcinoma (Ladoire et al. 
2013). HMGB1 binding to TIM3 can also suppress the immunostimulatory pathway in 
DCs. HMGB1-TLR2/4 interaction is essential for determining the immunogenicity of the 
dying tumor through cross presentation of the tumor antigens and promotion of the tumor 
specific Tc1/Th1 cell responses (Ladoire et al. 2013). 
We have found CD3 positive T lymphocytes (between 120-216 h post-treatment) and MPO 
positive neutrophil granulocytes/monocytes (between 72-216 h post-treatment) demarcating 
the destructed central tumor areas in mEHT treated xenografts. These inflammatory 
infiltrates can be consistent with the immunostimulatory effects of HMGB1 release from 
the nucleus and beyond (Ladoire et al. 2013). 
As it has become clear the ultimate outcome of DAMP related immune response to cancer 
cell death is rather complex and context dependent. Cell death is influenced by the type and 
localization/microenvironment of cancer cells, the cell death pathways activated, the type 
of immune cells interacting with the cancer and the efficiency of the recognition of cancer 
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antigens (Garg et al. 2013). In this project we used immunodeficient Balb/c (nu/nu) mice 
lacking mature T cells to host HT29 colorectal cancer xenografts. Therefore, this model is 
inappropriate for investigating proper immune response upon mEHT treatment thus the 
detected DAMP signals cannot be linked directly to ICD. However, the DAMP signal 
sequence revealed in this model support the feasibility of testing if mEHT treatment in 
immune competent animal models can directly promote ICD.  
Furthermore, some of the chemotherapeutic ICD inducers are already used on daily bases, 
but in combination with corticosteroids, which may demolish the potential immune 
response (Kepp et al. 2011). If a local treatment can induce DAMP and consequently ICD 
these may give rise to effective anti-tumor immune response. On the other hand mEHT 
treatment might destroy locally the leucocytes as suggested by elevated expression of 
caspase-3 in these cells, but does not eradicate them on a systemic level. 
 
 
Figure 20. Schema of mEHT induced spatiotemporal appearance of DAMP related to 
ICD in HT29 xenograft model. Modulated EHT induced ecto-calreticulin exposure, 
Hsp70 membrane appearance, followed by nuclear HMGB1 release and Hsp90 membrane 
translocation. Concomitant MPO and CD3 positive leukocyte were detected around the 
destructed tumor area. 
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Finally, as an important observation we found the significant elevation of TRAIL-R2 a pro-
apoptotic receptor mediating extrinsic programmed cell death signal, between 8-14 h post-
treatment. This can either be a direct consequence of the treatment, then the cell death 
subroutine should be external apoptosis mediated by caspase-8 or necroptosis mediated by 
RIP1 or RIP3 (Jouan-Lanhouet et al. 2012). TRAIL-R2 externalization can be a secondary 
effect related to the ER stress induced by unfolded protein response (Stolfi et al. 2012). The 
lack of caspase-8 cleavage or RIP1 or RIP3 activation leads to the conclusion that 
TRAIL-R2 elevation is more probably a secondary event (Jouan-Lanhouet et al. 2012). 
Heat may induce endoplasmic reticulum stress related unfolded protein response (Adachi et 
al. 2009), which can induce elevated TRAIL-R2 expression even in p53 mutant cell lines 
such as colorectal cancer cell lines including HT29 (Stolfi et al. 2012). This is further 
supported by that TRAIL-R2 positivity was observed in the periphery of the tumor 14 h 
post-treatment where no mitochondrial Bax or cytoplasmic cytochrome c release was 
observed. In line with this, a decrement in survivin was measured on the apoptosis protein 
arrays as it has also been referred in the literature (Stolfi et al. 2012). TRAIL upregulation 
upon mEHT treatment can potentially be exploited for potentiating TRAIL-R2 agonist 
tumor treatment with mEHT (Hellwig et al. 2012). Obviously, further investigations are 
required for revealing the endoplasmic reticulum stress related unfolded protein response. 
Furthermore, for an adequate therapeutic response through TRAIL or TRAIL agonists 
testing the pattern of decoy receptors (DcR1 and DcR2) is also crucial. TRAIL is the ligand 
of decoy receptors, however, decoy receptors lack death domains, therefore, the 
downstream signaling for any programmed cell death subroutine is insufficient through 
them. Not surprisingly, DcR1 and DcR2 can inhibit TRAIL-R1 and TRAIL-R2 (Wang 
2010).  
In summary, mEHT treatment can induce programmed cell death related tumor destruction 
in HT29 colorectal adenocarcinoma xenografts, which dominantly follows a caspase 
independent subroutine in line with spatiotemporal DAMP sequence that may be relevant 
for promoting immunological cell death. 
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8. CONCLUSION – NEW OBSERVATIONS 
 
1. A single shot mEHT treatment in an in vivo HT29 xenograft raised in Balb/c (nu/nu) 
mice cause significant tumor cell destruction with a peak of 7-fold increase at 72 h 
post-treatment compared to the untreated control tumors. 
 
2. Programmed cell death induced by mEHT in HT29 xenograft dominantly follows a 
caspase independent subroutine with mitochondrial permeabilization by Bax, the 
cytoplasmic release of cytochrome c and concomitant mitochondrial to nuclear 
translocation and activation of AIF resulting in DNA fragmentation as measured 
with the TUNEL assay. 
 
3. A single shot mEHT treatment related tumor cell stress can generate the 
spatiotemporal sequence of DAMP signals in the HT29 colorectal cancer xenograft 
model without any additional genetic or pharmaceutical intervention. Our data 
suggest that mEHT can be a potential local inducer of ICD, without a systemic 
interference with immune functions. 
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9. SUMMARY 
 
Electric field and concomitant heat induced by modulated electrohyperthermia (mEHT) can 
be selectively enriched in malignant tissue due to elevated glucolysis (Warburg effect), 
resulting in elevated conductivity and permittivity in cancer compared to non-malignant 
tissue. In this project we studied the mechanism and time course of tumor destruction and 
focused on spatiotemporal appearance of damage associated molecular pattern (DAMP) 
related to mEHT. 
Bilateral implants of HT29 colorectal cancer in the femoral regions of Balb/c (nu/nu) mice 
were treated with a single 30 min shot of mEHT. Tumors at 0, 1, 4, 8, 14, 24, 48, 72, 120, 
168 and 216 h post-treatment were studied for morphology, DNA fragmentation and cell 
death response related protein expression using tissue microarrays, immunohistochemistry, 
western immunoblots and mRNA microarrays. 
Modulated EHT treatment induced significant tumor destruction in HT29 xenografts with a 
peak of 7-fold increase compared to the untreated controls. The significant treatment 
related elevation of DNA fragmentation and apoptotic bodies between 24-72 h post-
treatment proved a programmed cell death response. This was associated with significant 
mitochondrial accumulation of Bax and cytoplasmic release of cytochrome c proteins 
between 8-14 h. Cleaved caspase-3 levels were low and mainly localized to inflammatory 
cells. The substantial cytoplasmic to nuclear translocation of 57 kDa activated fragment of 
apoptosis inducing factor was detected between 14-24 h. The cell death response was 
accompanied by the 4 h post-treatment upregulation of heat shock protein mRNA levels. 
The treatment resulted in spatiotemporal occurrence of a DAMP featured by significant 
cytoplasmic to cell membrane translocation of calreticulin at 4 h, Hsp70 between 14-24 h 
and Hsp90 at 216 h post-treatment. The release of high mobility group box1 protein from 
tumor cell nuclei from 24 h post-treatment was also detected. 
Modulated EHT treatment can induce programmed cell death related tumor destruction in 
HT29 colorectal adenocarcinoma xenografts, which dominantly follows a caspase 
independent subroutine in line with spatiotemporal DAMP sequence that may be relevant 
for promoting immunological cell death. 
DOI:10.14753/SE.2015.1802
64 
 
10. ÖSSZEFOGLALÁS 
 
Az elektromos tér és az általa generált hő (modulált elektrohipertermia- mEHT) szelektíven 
dúsul a malignus szövetben. A daganatos szövet megváltozott metabolizmusa, aerob 
glikolízis (Warburg hatás) hatására a malignus szövet vezetőképessége és permittivitása 
emelkedett a malignusan nem elfajult szövethez képest. Jelen tanulmányban a mEHT 
sejtpusztító hatás molekuláris szintű hatásmechanizmusát, valamint az immunogén 
sejthalálra (ICD) jellemző molekuláris mintázatot (DAMP) vizsgáltuk.  
A kísérletekhez HT29 kolorektális adenocarcinoma sejtvonalat injektáltunk Balb/c (nu/nu) 
egerek mindkét oldali femorális régiójába. A jobb oldali tumorokat egyszeri 30 perces, 
mEHT-val kezeltünk. A mintavételezés 0, 1, 4, 8, 14, 24, 48, 72, 120, 168 és 216 órával a 
kezelést követően történt. A minták morfológiai, mRNS expressziós, DNS fragmentációs 
vizsgálatára, valamint a sejthalállal kapcsolatos fehérjék expressziójának analízisére került 
sor western blottal valamint szöveti multiblokkokon immunperoxidáz és 
immunfluoreszcencia vizsgálatokkal.  
A morfológiai vizsgálatok alapján megállapítottuk, hogy a mEHT kezelés HT29 
xenograftokban maximálisan hétszeres sejtelhalást eredményezett a kezeletlen tumorokhoz 
képest. A kezelés hatására szignifikáns DNS fragmentációt és apoptotikus testek 
megjelenését detektáltuk 24–72 órával a kezelést követően. 8–14 órával a kezelés után a 
pro-apoptotikus Bax mitokondriális felhalmozódását és a citokróm-c mitokondriumból való 
kiáramlását észleltük. Ugyanakkor hasított kaszpáz-3 pozitív sejteket kizárólag a MPO 
vagy CD3 pozitív gyulladásos sejtekben találtunk. 14–24 órával a kezelést követően az 
apoptózis indukáló factor 57 kDa-os fragmentjét detektáltuk western blottal és sejtmagi 
előfordulását imunnhisztokémiai vizsgálattal. 4 órával a kezelést követően hő sokk fehérjék 
mRNS szintű szignifikáns emelkedését detektáltuk. Fehérje szinten DAMP mintázatot is 
észleltünk, így citoplazma membrán dúsulását detektáltunk 4 órával a kezelést követően a 
karetikulin, 14-24 óránál a Hsp70 és 216 óránál a Hsp90 esetében. A sejtmagokból a 
HMGB1 kiáramlás 24 órával a kezelést követően kezdődött. 
Összefoglalva: a HT29 humán kolorektális adenokarcinóma modellben a mEHT kezelés 
elsősorban kaszpáz független programozott sejthalált váltott ki és egyidejűleg indukálta az 
immunogén sejthalálra jellemző DAMP megjelenését.  
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